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INTRODUCTION TO AOGIN, THE ASIA OCEANIA
RESEARCH ORGANISATION ON GENITAL
INFECTIONS AND NEOPLASIA
SuzanneGarland
Theneed
Cancer prevention and control are among the most impor-
tant public health challenges facing the world today.
Worldwide, carcinoma of the uterine cervix is the second
mostcommoncancerinwomen.Incidentcasesareestimated
to be approximately 470600 per annum, with almost 80%
occurring in the developing world.
Theorganisation
The AOGIN concept was based upon an expert multidisci-
plinary group developed overseas—the European Research
Organisation on Genital Infection and Neoplasia (EURO-
GIN).
This organisation crosses professional boundaries, unit-
ing gynaecology, sexual health, dermatology, epidemiol-
ogy/public health, pathology, biology, oncology, and basic
science.
Objectivesandactivity
AOGIN aims are to promote and develop research, training,
screening, prevention, and information concerning genital
infections, precancers, and cancers in women.
New breakthroughs in diagnostics, treatment, and pre-
vention will provide both opportunities and challenges in
upcoming years. AOGIN activity should assist decision-
makingandplanningsothatthemostcost-eﬀectivegainscan
be made for each nation.
The work will focus on
(1) collaboration and research,
(2) scientiﬁc exchanges, education and training,
(3) information provision,
(4) surveys and audits.
Firstmeeting
The ﬁrst AOGIN Meeting was held in Kota Kinabalu,
Malaysia, in July 2005. It was coordinated by an executive
committee that included leading physicians from Australia,
Japan, Korea, Singapore, India, and China.
The meeting was generously supported by a number
of pharmaceutical and diagnostic companies, and received
helpful input from professional societies. Delegates from 23
nations attended the meeting and gave insights into HPV
and cervical cancer epidemiology and management in their
countries.
CERVICAL CANCER AND HPV:
THE ESSENTIAL EPIDEMIOLOGY
Xavier Bosch
Globalperspective
Globocan data suggest that around 470000 cases of cervical
cancer are diagnosed worldwide every year [1]. While this2 Infectious Diseases in Obstetrics and Gynecology
is a far lower incidence than for breast cancer (1050000 di-
agnoses per year), cervical cancer remains the second most
common cancer for women. Colon/rectal cancer, lung can-
cer, and stomach cancer, which can aﬀect both men and
women, all have lower incidences at 446000, 387000, and
418000, respectively.
The relative incidence for diﬀerent cancers varies signiﬁ-
cantly between regions. In North America, cervical cancer is
not among the leading seven cancers diagnosed in women,
nor among the top seven cancers that result in death.
Av e r yd i ﬀerent scenario exists in Central/South Amer-
ica (where cervical cancer is the second most frequent cancer
diagnosis and cause of death), Africa (most frequent cancer
diagnosis and cause of death), and Asia (second most fre-
quent cancer diagnosis and fourth most frequent cause of
death).
It is estimated that the lifetime risk of any woman experi-
encing cervical cancer is 3–4%. Yet age adjusted rates (AARs)
varyfromashighas42.7inEast ernA fricaand38.2inSou th-
ern Africa, to as low as 5.8i nW e s t e r nA s i a[ 1].
Humanpapillomavirus
HPV is a small DNA virus that demonstrates signiﬁcant ge-
netic variation, with more than 100 types identiﬁed and se-
quenced to date. Two oncogenes associated with the virus
have been identiﬁed, and are known as E6 and E7, which
have the ability to degrade the proteins of the cellular genes
p53 and Rb, thus interfering with essential mechanisms of
cell proliferation and repair. A diﬀerent section of viral DNA
has been shown to be immunogenic and appears to generate
a protective response.
The pathogenicity of the viruses varies: some types (such
as 6 and 11) are linked to genital warts, while others (such
as 16 and 18) are frequently seen in women diagnosed with
invasive cervical epithelial abnormalities or cancer. Infection
does not inevitably lead to pathological changes; regression
occurs in some cases.
Interestingly, HPV prevalence among the general popu-
lation is signiﬁcantly higher in North-Eastern Africa (34.0%)
and Central/South America (23.5%) than in other regions.
In Asia, incidence is higher in the East (13.8%) and South-
central (11.9%) areas than in Japan-Taiwan (7.4%) and
South-East Asia (4.9%).
HPVandcervicalcancer
Worldwide, a review of the prevalence of the 11 most com-
mon HPV types in HPV-positive cervical cancer cases (n =
2855)indicatesthatalthoughfrequenciesvaried,HPV16fol-
lowed by HPV 18 were most commonly detected in Africa,
Central-South America, South Asia, and North America.
HPVs 45, 31, and 33 were also seen globally [2].
H P V s1 6a n d1 8a p p e a rt ob em o s tf r e q u e n ti nc a s e so f
high-grade squamous intraepithelial lesions (HSIL) or inva-
sive cases of squamous cell caroinoma (SCC), although the
relative incidence of diﬀerent types varies in diﬀerent regions
[3].
Epidemiologyandmanagement
HPV is now established as a causative agent for cervical can-
cer, with 95% of cervical cancer specimens testing positive
for HPV DNA using GP5+/6+ primers PCR. Cofactors that
increase the risk of cervical cancer include high parity, oral
contraceptive use, smoking, and HIV infection. Diet, low so-
cioeconomic status, and other genital infections also appear
to inﬂuence risk.
The variation in distribution and age-prevalence for dif-
ferent types of HPV varies between countries. However, the
distribution of HPV types in cervical cancer shows universal
dominance of HPVs 16 and 18, with some variability there-
after [4]. The 15 types that explain 95+% of cervical cancer
do not show signiﬁcant variability.
HPV: VIROLOGY AND EPIDEMIOLOGY
IanFrazer
Humanpapillomavirus(HPV)
Papilloma viruses are double-stranded DNA viruses that
replicate only in the skin cells of their host species. They do
not grow in cell culture.
There are many diﬀerent immunologically distinct types
of HPVs, which have been linked to speciﬁc conditions—
genital warts (HPVs 6, 11); genital cancer (HPVs 16, 18);
epidermodysplasia verruciformis EV (HPVs 5, 8); and cuta-
neous warts (HPVs 1, 2).
HPV infects stem cells in the skin. Because the virus does
not kill the host cell, it must wait for cell shedding (desqua-
mation) to escape. The viruses do not generate an inﬂamma-
tory response.
In cancer-causing HPVs, recognition by the immune sys-
tem relies on growth-regulating segments known as E6 and
E7. These proteins extend cell proliferation and retard cell
diﬀerentiation, but do not inevitably result in malignancy.
Cancerous transformation occurs only in vivo. On a cellular
level, it is not known why some HPV types are more likely to
induce cancer than others.
Cervicalcancer:theHPVconnection
HPV infection is common and is usually acquired soon af-
ter sexual activity commences. Most HPV infections regress
without treatment. Less than one in 50 women infected with
HPV16willshowresidualinfectionafter5years.Progression
of infection to precancer is slow and uncommon [5].
Yet every year, around 250000 women die as a result of
cervical cancer, and HPV is almost always present (99.8%).
The most common type of HPV seen in cervical cancer is
HPV 16 (∼ 60%).
Preventingcervicalcancer
Currently,theonlymethodofpreventingcervicalcanceristo
identify precancerous lesions early and treat them. However,
vaccines may prevent infection with high-risk HPV viruses,
breaking the cycle far earlier.Sebastian Faro et al 3
Although the response is slow, HPV generates a type-
speciﬁc immune reaction [6]. While this virus is not highly
immunogenic, regression of HPV is dependent on this
immuneresponse—itoccurslessfrequentlyinimmunocom-
promised patients such as renal transplant recipients. Details
of this immune response are not completely understood, but
humoral, cellular, and innate immunity may all play a role.
HPVserologyandvaccinationresponses
The WHO recognised that without a standard reference
serum to enable laboratories to standardise the calibration
of HPV antibody testing, monitoring of vaccination pro-
grammes would be unreliable.
Test sera (particularly HPV 16) were distributed to 10
interested laboratories. Although all laboratories ranked the
sera in the same order, there was signiﬁcant variation in cut-
oﬀsforseropositivity.Thestudydemonstratedthattherewas
no universal ability to rank weakly reactive sera and to avoid
cross reactivity [7].
Suﬃcient positive serum is being gathered to make a ref-
erence serum, which may be available by the end of 2006.
HPV DNA TESTING: ASSAYS AND STANDARDS
SuzanneGarland
ImprovingdiagnostictestingforHPV
Laboratory procedures with known, consistent speciﬁcity
and sensitivity for detecting and typing HPV are needed to
conduct eﬀective epidemiological surveys and vaccine evalu-
ation. The standardisation of HPV assays is still evolving and
requires external quality assessment.
HPV DNA testing may be used clinically for
(i) screening, either alone or as an adjunct to cytology,
(ii) triage of patients with uncertain Pap results,
(iii) monitoring patients post-treatment.
HPVdetection
The presence of HPV can be identiﬁed by
(i) cytology (Pap smears),
(ii) histology,
(iii) electron microscopy,
(iv) immunohistochemistry (identiﬁcation of group-
speciﬁc antigen),
(v) molecular tests (including in-situ hybridisation, dot
blot techniques and others requiring ampliﬁcation of
viral DNA),
(vi) serology (detection of capsid proteins or VLPs).
Ampliﬁcation of viral DNA may be through target ampliﬁca-
tion (PCR) or signal ampliﬁcation (Hybrid Capture II).
The Hybrid Capture II Assay (HC II) has been approved
by the FDA and is available in microtitre format. An exfoli-
atedcervicalsampleisassayedagainstdiﬀerentprobegroups.
This technique involves ﬁve speciﬁc stages and results are not
type-speciﬁc, although low- and high-risk probe mixes are
available.
PCRishighlysensitive,permitsbothdetectionandgeno-
typing, and allows testing of diﬀerent sample types includ-
ing archival samples with poorer quality DNA. However, in-
hibitors in clinical specimens can lead to false-negative re-
sults, and contamination may result in false-positives. Most
assays target the L1 region of viral DNA, but primers and de-
tection systems vary.
ELISA-based microtitre plate format, reverse line blot/
strip assays, and microarray DNA chip assays can be used for
PCR-based genotype-speciﬁc detection.
Roche has developed AMPLICOR HPV which uses a mi-
crowell plate-based ELISA technique to amplify and detect
13 high-risk HPV types.
In a preliminary study at the Royal Women’s Hospital
in Melbourne, Australia, HC II and AMPLICOR were com-
pared by testing a range of samples; outcomes were com-
pared to histology/cytology results. Both assays were posi-
tive for the 1 case of cancer, and of 38 samples with histo-
logically conﬁrmed HSIL lesions, Amplicor demonstrated an
89% sensitivity comparedwith79%forHCII.Thetests were
less sensitive in predicting LSIL lesions: HC II and Amplicor
detected 50% and 59%, respectively. The two tests had simi-
lar numbers of positives (∼ 9%) for those with normal his-
tology, although these were a high-risk population, having
previously had an abnormal Pap.
Line blot or line-probe assays can be used to recognise
diﬀerent genotypes of HPV. These PCR techniques are de-
tailed and intensive.
Expandinguse
HPV DNA testing is an objective test that will play an in-
creasing role in the management of women with minor cy-
tological abnormalities, as the results are more sensitive and
reproducible than Pap smears in determining a woman’s risk
of having underlying HSIL, the precursor lesion for cervical
cancer [8]. In combination with Pap cytology, the negative
predictive value approaches 100%, resulting in fewer unnec-
essary colposcopies.
However, communication, education, and counselling
will be required for women testing positive to HPV DNA.
There is a high prevalence of HPV in clinically normal young
women, and most infections are transient. Repeat testing is
the sole means of determining HPV persistence.
Movingforwardinastandardisedway
International standard reagents provide a helpful tool for
high-quality HPV ampliﬁcation, detection, and genotyping.
The WHO has a panel working towards standards that will
enable laboratories to measure their results in relation to
other groups.
Knowing speciﬁcity and sensitivity of particular HPV
genotyping methods is crucial for epidemiological surveys,
vaccine evaluation, and ongoing monitoring of vaccine
performance following deployment. Complete protection4 Infectious Diseases in Obstetrics and Gynecology
against persistent HPV infection in vaccinated women has
been demonstrated by two diﬀerent HPV preventative vac-
cines in independent studies [9, 10].
HPV detection or even persistence is not an appropri-
ate endpoint for preventative vaccine trials, as most infec-
tions are transient. Therefore,cervicalintraepithelial neopla-
sia (CIN) of moderate or high grade are being used as the
primary endpoint for vaccine trials. Once this surrogate end-
point has been proven, virological or immunological corre-
lates of protection may be considered for future evaluation
and product development.
HPV TESTING IN CLINICAL PRACTICE
HenryKitchener
PotentialrolesforHPVtestingincervicalscreening
The most important clinical value of HPV testing in the
lower genital tract is to distinguish women at very low risk
of malignancy from those at some risk.
In cervical screening, the principal roles that HPV testing
may play are
(i) in primary screening,
(ii) in following up the treatment of cervical abnormali-
ties,
(iii) triage of mild abnormalities.
Studyﬁndings
The ASCUC-LSIL triage study (ALTS) investigated the sensi-
tivity of HPV testing using HC II combined with repeat cy-
tology in detecting CIN3+ lesions (Table 1)[ 11].
FurtherresultsfromtheALTSstudy,inwhich897casesof
low-grade squamous intraepithelial lesion (LSIL) and 1193
casesofHPVDNA-positiveASCUSwerefollowedfor2years,
suggested that LSIL lesions and HPV-positive ASCUS are
clinically equivalent [12]. Initial colposcopic detection of ob-
viously prevalent CIN2+ reduces risk. However, for the re-
maining women who have CIN ≤ 1 on colposcopy and di-
rected biopsy, the risk for subsequent CIN grade 2 or 3 is
approximately 12% over 2 years.
The HPV in addition to routine testing (HART) study
looked at the management of women who tested positive
for high-risk types of HPV, but had negative or borderline
screening abnormalities [13]. HPV testing was more sensi-
tive than borderline-or-worse cytology (97.1% versus 76.6%,
P = .002), but less speciﬁc (93.3% versus 95.8%, P<. 0001)
for detecting CIN2+. Surveillance at 12 months was as eﬀec-
tive for monitoring progression as immediate colposcopy.
Fromstudyresultstoclinicalpractice
A meta-analysis to assess the accuracy of HPV DNA testing
asanalternativetorepeatcytologyinwomenwhohadequiv-
ocalresultsonapreviousPapsmearsuggeststhatHCIIassay
has higher sensitivity and similar speciﬁcity than the repeat
Pap smear (ASCUS as threshold) for CIN2+ among women
in this patient group [14].
Table 1: Triage test performance of HC II and cytology [11].
%
sensitivity
%
referral
Positive
predictive
value
Negative
predictive
value
CIN3+
HC II 96.35 6 .11 0 .09 9 .5
HSIL+ cytology 44.16 .93 7 .59 9 .5
LSIL+ cytology 64.02 6 .21 4 .39 7 .1
ASCUS+ cytology 85.35 8 .68 .59 7 .9
CIN2+
HC II 95.95 6 .11 9 .69 8 .9
HSIL+ cytology 34.86 .95 8 .19 2 .0
LSIL+ cytology 59.22 6 .22 5 .99 3 .6
ASCUS+ cytology 85.05 8 .61 6 .79 5 .8
HPV testing has a high negative predictive value and al-
though the positive predictive value is lower, it oﬀers consid-
erable beneﬁts in triaging patients. It can also assist decision
makingonbehalfofwomenwithmildcytologicalabnormal-
ities.
BASELINE RESULTS OF HPV DNA TESTING IN
EUROPEAN SCREENING STUDIES [15]
JackCuzick,ChristineClavel,UlliPetry,PeterSasieni,
ChrisMeijer,PhilippeBirembaut,AnneSzarewski,
AchimSchneider,ShaliniKulasingam,SamRatnam,and
ThomasIftner
Objectivesformeta-analysis
The objectives for reviewing HPV screening trials were to
(i) determinetheage-speciﬁcHPVprevalenceindiﬀerent
European areas,
(ii) evaluate the sensitivity and speciﬁcity of HPV testing
in women attending routine screening,
(iii) compare the sensitivity and speciﬁcity of HPV testing
with that of routine cytology.
Studies
Studies included were from the UK (HART [13], Hammer-
smith [16]); France (Reims [17]); Germany (Hannover and
Tuebingen[18],Jena[19]);andtheNetherlands(Amsterdam
[20]) (Figure 1).
Comparisons were also made with North American
screening studies reported by Ratnam et al [21] and Kulas-
ingam et al [22].
TestingforHPV
Across the European studies, the HC II test for HPV had a
sensitivity of 96% and speciﬁcity of 92%, whereas cytology
based on Pap smears had a sensitivity of 63% and speciﬁcity
of 96%.Sebastian Faro et al 5
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Figure 1: Age and HPV positivity.
Although the performance of HPV testing is similar in
diﬀerent areas of Europe, the sensitivity of cytology is highly
variable between countries.
HPVasasoleprimaryscreeningtest
There are a number of potential advantages in using HPV
testing (HC II) as the sole primary screening test for cervi-
cal cancer. Due to its automated, highly sensitive, and ob-
jective nature, results are less variable and quality control
is simpler. Cytology could thus be reserved for 6–10% of
women; screening would be undertaken in more detail by
a smaller number of more focused cyto-screeners. Triage of
HPV-negative ASCUS/LSIL lesions would be eliminated.
Screening intervals could be longer with potential cost
savings and greater convenience.
TREATMENT OF PREINVASIVE CERVICAL LESIONS:
IS THERE ANY VALUE IN TESTING FOR HPV DNA
POST-TREATMENT?
JeffreyTan
Treatingpreinvasivecervicallesions
A 2001 Cochrane report suggests there is no overwhelmingly
superior surgical technique for eradicating CIN [23].
Regardless of treatment approach, the risk of persistent
disease is greater when the lesion is large, or the patient is
>30 years of age or has been treated previously and/or is a
carrier of HPV types 16 or 18 [24].
AftertreatmentforCIN
Between 1998 and mid-2003, 3647 women were treated at
Melbourne’s Royal Women’s Hospital (RWH) for CIN.
Among those who returned 3–6 months postsurgery,
21% returned an abnormal Pap smear/histology. By 9–14
months, persistent low-grade abnormality was seen in 9.4%
and high-grade abnormality in 0.7% of women.
Residual disease following large loop excision of the
transformation zone (LLETZ) surgery may be missed in
screening when cytology is used. In a 2002 review of 90
women,cytologyhadapositivepredictivevalueof81.3%and
an e g a t i v ep r e d i c t i v ev a l u eo f5 5 .4% [25].
Results from RWH comparing cytology and colposcopy
for detecting SIL post-operatively suggest that cytology is
more speciﬁc than colposcopy (82.6% versus 24.4%), but far
less sensitive (46.0% versus 90.5%).
As cytology and colposcopy both present diﬃculties in
sensitivity and speciﬁcity, HPV testing may provide an al-
ternative approach. A review of 11 studies published from
1992 to 2002 demonstrated that among 900 women treated
for CIN, 204 had residual or recurrent cellular abnormali-
ties and incidence of HPV was 83%; among 696 women with
apparently successful outcomes, the incidence of HPV DNA
was only 15% [26].
A meta-analysis of 11 studies suggests that the combi-
nation of HPV testing with cytology is promising for post-
treatment evaluation [27].
ThevalueofHPVDNAtestingpost-treatment
A study currently underway at RWH aims to determine
whether HPV DNA (HPV HC II test) is a marker for recur-
rent disease following surgical management of CIN. Since
2001, over 1500 women have been recruited at the time of
surgical treatment for CIN. Overall, 64% of the women had
high-risk HPV detected at surgery. For women with HSIL
conﬁrmed histologically at surgery, 79% had high-risk HPV
DNA detected on the hybrid capture test.
ThesewomenarereviewedregularlyandateachvisitPap
and HC II tests are undertaken and colposcopy performed.
Theoverallpositiverateforhigh-riskHPVDNAfellfrom
31%at3–9monthsto20%by21–25monthspost-treatment.
If Pap cytology and HC II were negative 12 months after
treatment, only 0.6% of women had HSIL.
Thisstudyisstillongoing,althoughthesepreliminaryre-
sults suggest that the negative predictive value of high-risk
HPV DNA holds promise as a marker for the adequacy of
HSIL treatment when performed ≥ 12 months post-surgery.
Revised guidelines for post-treatment assessment of cer-
vical lesions will be introduced in Australia in July 2006. Col-
poscopy and cytology should be undertaken 4–6 months af-
ter treatment for HSIL. Cervical cytology and HPV typing
will be used at 12 months, then annually until negative re-
sults for both tests are obtained on 2 consecutive occasions.
From that time on, Pap smears will then be at the recom-
mended screening interval of 2 yearly.
SINGAPORE: CANCER SCREENING AND
EPIDEMIOLOGY
EHTay
Assessingbeneﬁts,risks,andcostsofcancerscreening
In Singapore, cancer causes more deaths than heart disease
[28]. Cervical cancer is the fourth most prevalent cancer
in Singapore, and based on 1993–1998 data, has an ASR of
14.3/100000. Breast, lung, colorectal cancers, and, in recent6 Infectious Diseases in Obstetrics and Gynecology
years, ovarian cancers, have a higher incidence [29]. Breast,
colorectal, and ovarian cancer rates are increasing; lung and
cervical cancer are decreasing, a trend believed to be linked
to behavioural factors [29].
Current cervical screening recommendations in Singa-
pore recommend Pap smears every 3 years for women from
timeofﬁrstintercourseorfrom25yearsofageuntil65years.
A cervical screening programme for Singapore was ﬁrst pro-
posed in 1992; however, breast screening was given priority.
In 1997, a plan for a pilot study was submitted and accepted
by the Health Promotion Board. Following 5 years of devel-
opment, the pilot programme is currently underway. Roll-
out nationally had begun in 2004.
Short-term challenges for the project are to
(i) ensurecoverageacrossthepopulation, througheduca-
tion of doctors and women
(ii) prepare laboratories and standardise reporting—a lo-
cal systematic reporting system has been adopted,
(iii) eﬀectively manage and treat women with abnormal
smears,
(iv) address the issue of false-negative Pap smear results.
Past failures of cervical screening [30] attributable to lack of
adequate quality control, rather than to technological limita-
tions of the Pap test, has shifted the focus from new technol-
ogy(suchasautomation)[31]towardqualityassurance[32].
Retrospective review has highlighted areas for laboratory ed-
ucation and quality improvement eﬀorts, and strong liabil-
ity concerns have prompted the introduction of governmen-
tal regulation of laboratories, including obligatory accredita-
tion.
Prophylacticvaccination
HPVvaccinationhasthepotentialtobecomethesecondpro-
phylacticvaccinecapableofreducingtheincidenceofcancer,
following the success of hepatitis B vaccine in reducing hep-
atocellular carcinoma in some areas of the world [33].
Two vaccines for HPV are currently in late-stage devel-
opment. However, decisions on vaccine types, eﬃcacy, and
usage will await the outcomes of trials currently underway,
such as the FUTURE II study of a quadrivalent vaccine in
young women in the USA and Brazil, and the testing of a bi-
valent vaccine by the GlaxoSmithKline HPV Vaccine Study
Group.
As a primary prevention, vaccination oﬀers the advan-
tage of being able to be administered without speciﬁc train-
ing. In the long-term, vaccination against oncogenic HPV
should reduce the incidence of persistent infection and sub-
sequently of cervical cancer mortality. As part of a screen-
ing programme, the role and cost-eﬀectiveness of prophylac-
tic vaccines will be inﬂuenced by age at the time of vacci-
nation, level and duration of immunoprotection, epidemi-
ology of local HPV types, and cost of the vaccine [34]. In
Asia, while squamous cell cancer is most frequently associ-
ated with HPVs 16 and 18, which are predominant in most
countries of the world, there is some evidence that HPV 52
and 58 are more prevalent [35].
Considerations for planners include
(i) uncertainty about the role and response of antigenic
HPV subtypes in cervical cancer causation,
(ii) the impact vaccination will have on frequencies of
nontargeted HPV types,
(iii) the need to vaccinate men as well as women.
The impact of HPV vaccination on cervical cancer incidence
would not be immediate. If vaccination of young girls begins
in2010,itwouldbealmost20yearsbeforethedeclineofCIN
and cancer incidence may become apparent, in 2030.
Singapore plans to implement universal Pap smearing
from 2006; in light of the current breakthroughs, a strange
irony has emerged. While the implementation of a na-
tional cervical cancer screening programme brings the excit-
ing prospect of controlling a largely preventable cancer, the
countrymuststillfacethecostlyprocessofpreventingmisdi-
agnosisduetotheless-than-perfectsensitivityandspeciﬁcity
of the screening Pap test. The use of HPV testing and vacci-
nation holds signiﬁcant promise, but will not eliminate the
need for Singapore to address quality control in Pap smear
collection, cytology, and reporting [36].
Therapeuticvaccination
Preliminaryresultssuggestthatvaccinesmayalsohavethera-
peutic beneﬁts in women showing precancerous CIN lesions
[37, 38]. It appears that vaccines may stimulate the immune
system and cause the regression of precancerous CIN 1, CIN
2, and CIN 3 lesions when given locally.
ORGANISATIONAL ASPECTS OF SUCCESSFUL
SCREENING PROGRAMMES IN DEVELOPED
COUNTRIES: THE ENGLISH MODEL
HenryKitchener
Assessingbeneﬁts,risks,andcostsofcancerscreening
Inplanningacancerscreeningprogramme,eachcountrywill
develop guidelines based on the best available estimates of
costs, beneﬁts, and risks. Guidelines can be reviewed in light
ofemergingevidenceaswellasnewdiagnosticandtreatment
options.
Evaluation of a programme’s coverage should consider
the age of eligible participants, the frequency of testing, and
community awareness of, and access to, the programme. All
will impact on cost and eﬀectiveness.
Recommendations on the age of initiation and frequency
of cervical screening vary between European countries. Van
Ballegooijen et al compared the relative cost-eﬀectiveness of
programmes in European countries based on recommended
screening age ranges and intervals and coverage (Table 2)
[39].
Sasieni et al used UK data to compare the incidence of
cervical cancer in diﬀerent age groups of women against
the number of years since their last negative screening re-
sult [40]. His ﬁndings revealed that less frequent screening
may confer greater advantages in older women (>40 years)
compared with younger women. He found that 5-yearlySebastian Faro et al 7
Table 2: †Reduction (%) in life years lost according to policy and
coverage.
Netherlands, Beligum, France Germany
Finland Greece, Italy, Spain
Starting age 30 years 25 years 20 years
Interval 5 years 3 years 1 year
Ending age 60 years 64 years 72 years
Lifetime no. tests 7 14 53
Interval coverage % Reduction in life-years lost
25 21 24 25
50 42 47 50
75 62 71 75
100 84 94 99.9
†Adapted from Ballegooijen (2000).
screening oﬀers considerable protection (83%) against can-
cer at ages 55–69 years; annual screening provides only mod-
est additional protection (87%). On this basis the cervi-
cal screening programme now oﬀers 3-yearly and 5-yearly
screening for women aged 25–50 and 50–64 years, respec-
tively.
The proportion of women in the community who are
screened at the recommended frequency will also inﬂuence
any evaluation. In 2004, around four in every ﬁve British
women aged 25–64 years had been screened for cervical can-
cer within the previous 5 years.
Primary care practices carry the prime responsibility for
the continuity of testing. A review of primary care organi-
sations in 2004 showed that coverage of eligible women in
diﬀerent practices varied from 70% to 90%.
Training and evaluation programmes in cytology and
colposcopy have been established. The majority of British
laboratories reviewed in 2003–2004 achieved 65–85% posi-
tive predictive values in their reviews of cervical smears (the
proportion of high-grade cytology associated with underly-
ing high grade CIN).
National computerised colposcopy data is not routinely
collected; for example in 2003–2004, more than 70% of
women with abnormal screening results saw a specialist for
colposcopywithin8weeks.Thiswasfollowedbyadiagnostic
biopsy in 40% of cases, and 19% had lesions excised on that
ﬁrst visit. In 37% of referred patients, colposcopy appeared
normal and no procedure was required.
New options such as HPV DNA testing, the availabil-
ity of liquid-based cytology and a growing awareness of the
relatively small beneﬁts gained through frequent testing for
women <40 years of age, are likely to inﬂuence the evolution
of the British screening programme.
CERVICAL CANCER IN THE PHILIPPINES
GeneraA.Manuel-Limson
Epidemiologyandscreening
In the Philippines, cervical cancer is the second most com-
mon cancer among women, behind breast cancer [41]. The
age standardised rate (ASR) is estimated to be 22.5/100000.
Incidence rises sharply in women >35 years of age. More
than 7000 new cases and almost 4000 deaths are seen each
year.
There is a close link between neoplastic cervical changes
and HPV persistence. Of 356 cases of SCC or ADC, 93.5%
tested positive for HPV, compared with only 9.1% among
a control group [42] .H P Vt y p e s1 6a n d1 8w e r em o s tf r e -
quently associated with cervical cancer.
As two in every three cases of cervical cancer are detected
in late stages of the disease, the median survival rate after
diagnosis is only 76 months; 5-year survival is 51.7%.
CervicalscreeninginthePhilippines
The Philippine health infrastructure is not suﬃciently devel-
oped to support a well-structured, cytology-based screening
programme. Pap smears are available through family plan-
ning clinics and relevant societies; however, screening is not
coordinated or appropriately targeted. Alternative strategies
for lowering the cervical cancer disease burden must be con-
sidered.
Cervicalcancerscreeningstudygroup
The Department of Health and the Medical Faculty at the
University of the Philippines reviewed screening options to
identify an approach that is feasible, cost-eﬀective, and repli-
cable, to reduce the need for extensive cytology services and
radical forms of treatment.
The study focused on
(i) knowledge,attitude,practice,andbehaviouralmodiﬁ-
cation,
(ii) validity and reliability standards for the screening test,
(iii) cost-eﬀectiveness,
(iv) health policy implications.
Four approaches to screening were compared:
(i) unaided acetic acid visualisation (AA),
(ii) magniﬁed acetic acid visualisation (MAA),
(iii) Pap smear using spatula (S),
(iv) Pap smear using cervical brush (CB).
Women 25–65 years of age were recruited for the study and
of those screened and interviewed, 13105 underwent col-
poscopy and were included in the data analysis.
Results
The results demonstrated the potential for acetic acid visual-
isation in a screening process (Table 3).
As a result of this trial, the study group recommended
that
(i) the acetic acid aided visual method be used as the
initial screen for cervical epithelial abnormalities at
health centres where Pap smear is not available,
(ii) all women showing abnormalities be referred for col-
poscopy, and biopsy, if necessary.8 Infectious Diseases in Obstetrics and Gynecology
Table 3: Comparison between acetic acid visualisation and Pap
smears.
AA† MAA Smear S Smear CB
Colposcopy
Sensitivity 50.3% 49.1% 21.0% 17.3%
(45–56) (44–54) (17–25) (13–22)
Speciﬁcity 94.1% 93.2% 99.1% 98.6%
(93–95) (92–94) (99–99) (98–99)
Biopsy
Sensitivity 37.1% 34.1% 14.6% 19.5%
(28–46) (26–42) (14–19) (10–29)
Speciﬁcity 92.6% 90.2% 98.2% 98.3%
(92–94) (90–93) (98–99) (98–99)
†Other studies: AA = 51–82%; PS = 13–85% snr.
Screening coverage for Filipino women is still low due to
inadequate healthcare personnel and a shortage of facili-
ties. There has been no sustained public health campaign to
promote the beneﬁts of regular screening. With many other
pressing public health priorities in the Philippines, funding
for cervical screening is limited.
INDIA: EPIDEMIOLOGY AND SCREENING OF
CERVICAL CANCER
NeerjaBhatla
EpidemiologyofcervicalcancerinIndia
Cervical cancer is the most common neoplasm in Indian
women, with 126000 new cases and 70000 deaths each year.
Incidence is higher than in Eastern Asia [1].
Across India, AARs vary greatly from ∼ 55/100000 in
Ambillikai to <18 in Mumbai and Trivandrum [43]. Across
India,cervicalcanceristhecommonestcancerreportedfrom
allcancerregistriesexceptthoseinMumbaiandDelhi,where
breast cancer is the commonest.
HPVandcervicalcancer
Persistent infection with HPV has been linked to almost all
cases of cervical cancer and 73–85% of CIN [44, 45].
In India, most studies previously focused on the preva-
lenceofHPVs16and18inthegeneralpopulation,whichwas
reported to be 7.5–9.6%—lower than global estimates—but
recent studies by IARC that looked at all high-risk types have
reported prevalence rates of 14–19%. Among Indian women
with CIN, 73% tested positive for HPV [46]. Types 16 or 18
were present in 73–82% of cervical cancer. However, a sys-
tematic study for all HPV types found 99.5% of tumours to
be positive for HPV [47]. In another study from the All In-
dia Institute of Medical Sciences (AIIMS), 98.1% of tumours
were positive for HPV. The most common types in these two
studies were HPVs 16, 18, 33, and 45.
The highest prevalence of HPV infection was previously
reported to be between 21–24 years of age, but more recently,
a systematic IARC study has shown that there is no distinct
age-related peak for HPV prevalence (Figure 2)[ 48].
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Figure 2: Age distribution of oncogenic HPV types in an Indian
population [48].
In a 2005 survey of HPV genotypes at the AIIMS in New
Delhi, HPV 16 was by far the most prevalent type, detected
in more than 35%, while HPV 18 prevalence was ∼3%.
CervicalcancerscreeninginIndia
The National Cancer Control Program has operated since
1972. Although cervical cancer is a stated priority, there has
been no coordinated cytology screening.
The current recommendation of the Indian Council of
Medical Research is that all women should have a single Pap
smear at approximately 35 years of age. In reality, screening
is opportunistic, frequently in research settings.
Developing countries must rely on less sophisticated re-
sources, such as visual inspection with acetic acid (VIA), vi-
sualinspectionwithaceticacidmagniﬁcation(VIAM),orvi-
sual inspection with Lugol’s iodine (VILI).
A series of trials has evaluated the eﬃcacy of these ap-
proaches in detecting high-grade disease. Results have been
very variable, with VIA having a sensitivity of 55 [49]–88%
[50, 51] and speciﬁcity of 63 [51]–94% [52]. Comparisons
between combinations of VIA, VIAM, and VILI have been
reported by Basu et al [49], Sankaranarayanan et al [53], the
IARC [54], and Shastri et al [55] with variable results.
In screening for cervical cancer, VIA oﬀers the following
advantages over alternatives:
(i) simple, easy-to-learn approach,
(ii) low startup and ongoing costs,
(iii) less reliance on infrastructure or medical specialists to
perform procedure,
(iv) immediacy of results,
(v) potential for integration into primary health care ser-
vices.
These need to be weighed against the disadvantages:
(i) moderate speciﬁcity—resulting in higher referral and
potential over-treatment,Sebastian Faro et al 9
(ii) dependenceonthepersondoingtheevaluation—need
for standard training methods and quality assurance,
(iii) lower accuracy in postmenopausal women.
IstherearoleforHPVtesting?
In detecting high-grade cervical lesions, the role of HPV
testing remains unclear. The test could be undertaken us-
ing samples collected by the patient. In a recent trial by
AIIMS, 93.5% of participants provided a satisfactory self-
sample, and concordance between physician-collected and
self-samples was high (93.8%).
HPV testing can be automated and provides a standard-
ised,objectiveresult.Incombination,itcanimprovethesen-
sitivity of Pap smears and VIA.
However,majorproblemsforthewidespreadadoptionof
HPV testing in India are its cost, the need for sophisticated
laboratory infrastructure, and repeat visits.
ThefutureofscreeninginIndia
Newer technologies may increase the speciﬁcity of testing
without loss of sensitivity, but are currently too costly for
generalised adoption.
Point-of-carediagnostictestssuchasVIAandthe“rapid”
HPV test will beneﬁt populations with poor compliance.
CHINA: HPV INFECTION AND CERVICAL CANCER
SCREENING STUDIES
You-linQiao
EpidemiologyofcervicalcancerinChina
Mortality data from the 1970s to the 1990s suggest that
China suﬀers relatively high cervical cancer mortality, par-
ticularly in the rural mid-west. Wudu in Gansu province
and Yangcheng in Shanxi had age-adjusted mortality rates of
>40/100000 in 1990–1992.
Better diagnosis and treatment have reduced deaths from
cervical cancer, but the improvement is not uniform and
mortality rates are unchanged in some counties.
Statusofcervicalscreening
There are no national screening programmes for cancer in
China. In the case of cervical cancer, limitations include the
nationwide shortage of cytologists.
In late 2003, a national cancer prevention and con-
trol strategy was ﬁnalised and endorsed by the Ministry of
Health, following consensus meetings for early detection and
treatment across nine cancer types.
Two demonstration centres for cervical cancer preven-
tion and control have been established in Shenzhen (South-
East China) for high resources settings and Xiangyuan
(North-West China) for low resources settings [56]. A gov-
ernment recommendation that all women should have at
least one screen between 35 and 65 years of age is still pend-
ing.
CervicalcancerresearchinChina
The ﬁrst Shanxi Province Cervical Cancer Screening Study
(SPOCCS I) included 1997 women who underwent a cer-
vical evaluation using HPV self-test, optical biopsy, liquid-
based cytology (ThinPrep), VIA, direct testing for HPV, or
colposcopy with biopsy [57].
A second study (SPOCCS II) included >8000 women
who submitted a self-sample for HPV at their village and
subsequentlyvisitedtheclinicforHPVDirectTest,LBC(Au-
toCyte), and VIA [58]. Those with abnormalities (n = 3252)
underwent colposcopy and biopsy. Women with CIN 2+ le-
sions were treated; those with CIN 1 lesions will be followed
up in 12 months.
In both studies, women with cervical cancer or CIN
2+ lesions on biopsy were likely to be infected with HPV
(>95%). Even for women with CIN 1 lesions, the at-
tributable risk of HPV is as high as 95%. The incidence of
HPV among women with normal biopsies was <15%.
Persistent HPV infection was higher among women aged
50–54 years than younger women in Shanxi, but there were
marked diﬀerences in the age-related curves for women in
rural areas versus cities.
Riskcofactors
Extensivelifestyledatawerecollectedcoveringsexualhistory,
child bearing, occupation, health, bathing practices, age at
menarche and menopause, education, and income.
Lifestyle had a signiﬁcant eﬀect on HPV and cervical
cancer prevalence in Shanxi. Risk factors that appeared to
contribute to the likelihood of cervical cancer were sub-
ject promiscuity (OR = 1.42); husband’s promiscuity (1.42);
bathing at a public house (1.23); postmenopause (1.22); and
current smoking (1.17). Surprisingly, education appeared to
slightly raise the likelihood of HPV.
When self-testing was compared with direct testing for
HPV,speciﬁcityforCIN2+wasidentical(85.9%),whilesen-
sitivity was higher on direct testing (97.6%) than for self-
testing (83.5%).
Evaluationofscreeningtests
In both trials, each screening test was compared with pathol-
ogy to determine accuracy in detecting moderate-high-grade
lesions (Table 4).
Conclusions
With high sensitivity (>96%) and moderate speciﬁcity
(86%), the HPV direct test could be used as a primary
screening test for cervical cancer risk. Self-sampling is simple
and less expensive; however, improvements in instructional
leaﬂets will be needed.
Combined HPV and VIA oﬀers potential for screening in
themid-westregionsofChina,butforconsistentresults,VIA
training will be essential.10 Infectious Diseases in Obstetrics and Gynecology
Table 4: Accuracy of screening tests for CIN 2+ compared with
pathology.
Screening test
Accuracy in detecting lesions
(versus pathology)
SPOCCS I SPOCCS II
(n = 1997) (n = 8497)
HPV self-test 85.8% 81.4%
HPV direct test 85.4% 84.0%
Pap-LBC ThinPrep 93.2% —
Autocyte — 81.7%
Colposcopy 76.7% 92.5%
Visual inspection 74.2% 89.1%
Fluorescent spectroscopy 0.1% —
HONG KONG: CERVICAL CANCER SCREENING
AnnieNYCheung
Womenandcervicalcancer
Hong Kong has a population of 6.8 million. Life expectancy
for women at birth was estimated to be 84.3 years in 2003.
During the period 1988–1992, Hong Kong’s ASR for
cervical cancer was ∼17; this is lower than that of the Thai,
Korean, Filipino, and Singaporean-Chinese populations, but
higher than in Japan (Figure 3)[ 59].
Historyofcervicalscreening
Until 2004, there was no centrally organised, systematic cer-
vical screening programme (CSP) in Hong Kong. Screening
was generally opportunistic or included as part of a gen-
eral checkup. Screening practices varied between diﬀerent
healthcare providers and there was little collaboration be-
tween public and private sector healthcare.
Approximately45%ofwomen,primarilythosewhowere
educated and health-conscious, were being screened. This
somewhat random coverage was not equitable or eﬃcient,
and was unlikely to be cost-eﬀective.
Despite this, the ASR for cervical cancer declined steadily
between 1983 and 2000, the most signiﬁcant fall being
among women 50–65 years of age. About 50% of cases are
diagnosed at stage 1.
AcentralisedcervicalscreeningprogrammeforHongKong
First approved in 2001, the Hong Kong CSP was launched in
March 2004. The goal is to reduce the incidence of, and mor-
tality from, cervical cancer by facilitating regular screening
for all patients at risk.
Stated objectives are to
(i) raise public awareness,
(ii) improve population coverage,
(iii) promote more equitable and eﬃcient screening,
(iv) build quality assurance into the services through pro-
fessional education and clear guidelines,
(v) support private sector activity.
Following statistical modelling, the target population was set
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Figure 3: Cancer of the cervix—age-standardised incidence and
mortality.
to include all women 25–64 years of age who have had sex.
After two clear annual checks, screening will be scheduled
every 3 years, and discontinued at 65 years if the previous
Pap smears are normal.
Using triennial screens, it was estimated that if coverage
raised to 80% of the population, there would be ∼75% de-
crease in the number of cases of cervical cancer.
It is hoped that the CSP will increase coverage from 43%
to 60% within 3 years, and to 80–85% in the long term.
During the period March 2004–June 2005, almost
150000 women were enrolled in the CSP. Based on age quin-
tiles, enrolment has been highest among women 40–44 years
of age. There are large variations between districts.
Thecommunicationnetwork
The CSP incorporates a centralised information system with
a website (available at http://www.csis.gov.hk) accommodat-
ing the input of data online.
The central registry will include screening results, fol-
lowup investigations, and demographic data, and will gener-
ate reminder letters to women due for screening. Practition-
ers will be emailed details of patients recalled, and alerted to
abnormal smears. The system will also provide data for on-
going evaluation and monitoring.
Public education regarding cervical cancer has not been
a priority in Hong Kong; therefore,communication and pro-
motion are priorities. Attention was drawn to the disease
when Anita Mui, a popular singer and movie star, died from
cervical cancer in December 2003. She was 40 years of age.
Her death coincided with the launch of the CSP and may
have aided receptivity.
Qualityassurance
All registered doctors and trained nurses may collect cervical
smears. Accreditation for participation is coordinated by the
Society for Colposcopy and Cervical Pathology. Health pro-
fessionals whose smears do not meet CSP minimum stan-
dards will be invited to attend refresher training.Sebastian Faro et al 11
Healthcare professionals who supply smears to the CSP
are provided with a training kit, which covers technical skills
and communication approaches.
A survey of women will be undertaken to gauge levels of
satisfaction with the CSP and the Pap smear.
The Hong Kong College of Obstetricians and Gynae-
cologists (HKCOG) has developed guidelines for the taking
of Pap smears and management of abnormal smears [60].
Other reference guidelines for pathology [61]a n dc y t o l o g y
[62] have also been prepared.
Cervical cytology laboratories operating under the CSP
must be approved by international bodies and the Hong
Kong laboratory accreditation scheme.
Testingandtriage
The CSP uses Pap smear cytology as the primary screen.
Among smears undertaken to date, 5.6% have shown ep-
ithelial cell abnormalities. Of the abnormal smears, 60–80%
were recorded as ASCUS. ASCUS patients were either re-
ferred for colposcopy or followed up with a further screen.
However, only 2–10% of ASCUS patients have serious dis-
ease [63].
HPV testing is currently under consideration as a means
of triaging patients with ASCUS and low-grade lesions.
At r i a lw a su n d e r t a k e nw h e r eA S C U Ss m e a r sw e r er e -
peated(n = 5579);onsecondreview,9.8%and1.7%showed
LSIL and HSIL lesions, respectively [64]. Patients with a pri-
mary ASCUS smear are at greater risk of developing SIL and
should be followed up.
A study of patients with ASCUS smears checked HPV
status using HC II testing. To date, 2309 samples have been
screened. Almost half (47.9%) were positive for high-risk
HPV strains. HPV-positive women with ASCUS were more
likely to have HSIL (P = .001) and LSIL (P<. 0001) detected
in their next cervical cytology samples.
Despite its beneﬁts, HPV typing remains expensive. In
addition, anxiety is generated when a woman is told that she
has been exposed to the virus. To ensure that information
is communicated eﬀectively to patients, it is important that
incorrect conclusions are avoided. For example, having been
told that cervical cancer is caused by HPV, an STD, patients
should not conclude that cervicalcanceris an STD. Similarly,
although sexual promiscuity increases the risk of HPV and
cervical cancer, an HPV-positive test does not imply that a
woman has been promiscuous. These communication chal-
lenges mean that HPV may not be an acceptable primary
screening test.
SCREENING TECHNOLOGIES TO ADVANCE RAPID
TESTING (START)
JohnSellors
STARTobjectives
This project aims to detect precancerous cervical lesions us-
ing newly developed rapid biochemical tests that are af-
fordable, accurate, simple to use, and appropriate for low-
resource settings.
PATH is currently working on two promising candidates:
(i) batch test (46 samples) for use in a small clinic or mo-
bile unit (results in ∼2 hours) in collaboration with
Digene Corporation (USA),
(ii) rapid strip test for a near-patient setting (results in
less than 20 minutes) in collaboration with Arbor Vita
Corporation (USA).
Following three years of research and development on the
new tests, the goal is to have a prototype for testing (veriﬁ-
cation, validation, ﬁeld tests) in 2006 and 2007. PATH has
negotiated an agreement with each private-sector partner to
supply the tests at a preferential price to the public sector in
developing countries for a period of ten years.
Thetests:currentprogress
The rapid batch test developed by Digene Corporation will
use an instant photo signal output. Images of samples will
be compared visually on a ﬁlm with positive and negative
controls.
The rapid strip test promises to diﬀerentiate between
transformation and infection by HPV. Arbor Vita Corpora-
tion technology detects a biomarker (E6 oncoprotein) which
correlates with neoplastic transformation of cells and main-
tenanceofcervicalcancer.TheELISAprototypeisnowbeing
adapted to an immunochromatographic strip format capa-
ble of detecting common high-risk HPV types. Eﬀorts are
focused on improving sensitivity.
In addition to using a cervical sample obtained by a
health care provider, vaginal sampling by a woman herself
or a provider is being investigated for both assays.
Collaborativearrangements
Clinical work will be undertaken in China (Cancer Insti-
tute Chinese Academy of Medical Sciences, Beijing, will co-
ordinate evaluation across several provinces) and India (Tata
Memorial Hospital, Mumbai, will oversee testing in the state
of Maharashtra).
Participation in the project oﬀers beneﬁts for the collab-
orating countries:
(i) approximately22000ruralwomenwillbescreenedfor
cervical cancer and treated, if necessary;
(ii) the project will provide job opportunities in outlying
districts;
(iii) biomedical workers will have opportunities for intel-
lectual exchange;
(iv) improved tests should provide a more aﬀordable, ac-
cessible, and acceptable screening option. Better pop-
ulation coverage would lower disease incidence and
mortality.
Movingforward
Throughout development collaborative input has been key,
withcontributionsfromusers(boththe“tested”andtesters),
private-sector partners, policy makers, and economists.12 Infectious Diseases in Obstetrics and Gynecology
For more information on the START project go to http://
www.path.org/projects/start project.php.
COSTS OF HPV DNA TESTING IN
CERVICAL SCREENING
JackCuzick
Introduction
HPV DNA testing has an estimated sensitivity of 96% and
speciﬁcity of 92%, making it considerably more sensitive and
o n l ym a r g i n a l l yl e s ss p e c i ﬁ ct h a nc yt o l o gy .T h e r ei ss u ﬃcient
evidencebasedonsurrogatemarkersthattheeﬃcacyofHPV
testing, using a validated system, as the primary screening
modality can be expected to be at least as good as that of
conventional cytology [68].
HPVtesting:potentialroleinprimaryscreening
HPV testing oﬀers a number of advantages when used in
combination with cytology in primary screening:
(i) higher sensitivity,
(ii) longer screening interval,
(iii) fewer inadequate samples.
If HPV testing were the sole primary screening test, cytol-
ogy could be used to triage patients who test positive. Self-
sampling may improve coverage.
PotentialcostimpactofreplacingcytologywithHPVtesting
Costreductionswouldresultfromlongerscreeningintervals,
fewerinadequatesmears,andavoidanceofborderlinesmears
in women not infected with HPV. However, lab costs would
be higher and surveillance rates would rise.
The cost impact of adding HPV testing to the British
cervical screening programme, and increasing the screening
intervalfrom3to5years,wasestimatedin1998[69].There-
sult suggested a fall in costs of around £30 million, or almost
25%.
EMERGING PREVENTION STRATEGIES: PROMISES OF
THE QUADRIVALENT HPVS 6, 11, 16, 18 VACCINE
(GARDASIL)
RichardM.Haupt
Rationaleforquadrivalentvaccinedevelopment
A vaccine protecting against HPV types 6, 11, 16, and 18 is
expected to substantially reduce the burden of HPV-related
diseases.
Merck’s quadrivalent HPV L1 virus-like particle (VLP)
vaccine, GARDASIL, has been well tolerated, immunogenic,
and eﬀective against HPV infection in early studies. Phase III
studies are underway to deﬁnitively evaluate the clinical and
public health impact of GARDASIL in adolescent and adult
men and women (Table 5).
Vaccineproﬁle
The quadrivalent vaccine comprises VLPs produced in a re-
combinant yeast [70]. The vaccine is adsorbed on the Merck
proprietary aluminium adjuvant, which strengthens its im-
munogenicity.
Injection volume is 0.5mL. Boosters are given at 2 and 6
months.
Clinicalprogramme
Thethree-phasedevelopmentprogrammeismovingtowards
completion.
(i) Phases I and IIa: preliminary assessment of immuno-
genicity and tolerability of diﬀerent doses of monova-
lent HPV L1 VLP vaccines.
(ii) PhaseIIb:immunogenicityandtolerabilityofdiﬀerent
quadrivalent vaccine dose formulations.
(iii) Phase III: demonstration of risk reduction for acqui-
sition of HPV infection and development of genital
warts and CIN 2/3 related to HPV types.
Resultstodate
HPV16vaccineproof-of-principlestudy
Thisearlystagetrialwasdoubleblindandplacebocontrolled
[9].Erolmentinvolved2391USwomenaged16–23years,re-
gardless of HPV status, who were followed for 4 years. Eﬃ-
cacy evaluation considered only women who were HPV 16-
na¨ ıve at baseline.
The primary endpoint of the study was persistent HPV
16 infection (positive vaginal or cervical swabs on ≥ 2c o n -
secutive visits), or HPV 16-related CIN (low-grade or high-
grade precancer on a tissue specimen from an abnormal area
on the cervix AND detection of HPV 16 virus in the same
lesion), with an additional corollary endpoint of single HPV
16 detection at last visit on record.
After 4 years, among those vaccinated there were seven
instances of HPV detection or CIN, compared with 111 cases
among the placebo group. This data demonstrate an eﬃcacy
level of 94% (P = 10−12). Signiﬁcantly, all seven cases in the
vaccine group were of single HPV detection at last visit on
record. The adverse event proﬁles were similar in the vaccine
and placebo groups.
In tests undertaken at 7 months, all vaccinated women
had signiﬁcantly higher levels of speciﬁc serum antibodies
than those on placebo, including those naturally infected
[71].
Dose-rangingandefﬁcacystudy
More than 1100 women aged 16–23 years, from the USA,
Brazil, and the EU, were enrolled in this double-blind,
placebo-controlled study, and followed for 3 years [70].
Three formulations of quadrivalent HPV vaccine or
placebo were given at enrolment, 2 months and 6 months.Sebastian Faro et al 13
Table 5: Contribution of HPV types 6, 11, 16, and 18 to HPV-related disease.
HPV Type Women Men
6/11 90% of genital warts [65, 66] 90% of genital warts [65, 66]
5–25% of low-grade cervical lesions Transmission to women
16/18
25% of low-grade cervical lesions 70% of AIN [66, 67]
70% of anal cancer
Transmission to women
70% of high-grade cervical lesions
70% of cervical cancer [67]
70% of other genital cancers
Immunogenicity was reviewed against each viral type
and women were monitored for persistent HPV in cervical
samples, CIN+ lesions, and genital warts.
Antibody response proved similar with the three vaccine
formulations, and all women given the vaccine had antibody
titres greater than those seen following natural infection.
The lowest dose combination has become the standard
formulation for GARDASIL.
Overall, four vaccinated women had persistent HPV in-
fections (HPV 16, 18), compared with 36 women given a
placebo vaccine. Eﬃcacy was 90% (P<10−3).
Adolescentimmunogenicitysubstudy
If HPV vaccine is to be used prior to sexual debut, an ad-
equate immune response must be demonstrated in adoles-
cents.
A randomised, double-blind, multicentre study has been
undertaken to compare immunogenicity, seroconversion,
and safety in 10–15-year-old males and females, and 16–23-
year-old females.
In all test groups, seroconversion levels at 7 months were
higher than the results recorded in the earlier adult trial.
PhaseIII
Phase III studies will include ∼ 20000 female patients at 150
sites across 33 ethnically diverse countries. Followup will be
for 4 years from ﬁrst dose.
The study in women began in 2001. A separate series of
studies will be conducted to evaluate the vaccine’s eﬃcacy in
men (heterosexual and homosexual). Men are a vector for
HPV in women, and suﬀer from genital warts and anal can-
cer (AIN is increasing among gay men).
The studies are characterised by an inclusive centralised
cervicovaginal evaluation programme. Women undergo Pap
testing at 6–12 month intervals.
Lookingahead
Prophylactic vaccines are the most eﬃcient means to reduce
the clinical impact of infectious disease. If proven safe and
eﬀective, a quadrivalent vaccine targeting pathogenic HPV
types will greatly reduce the burden of HPV-related diseases.
Preliminary studies for GARDASIL are promising, but
the Phase III programme will provide a deﬁnitive assessment
of the clinical utility of the vaccine.
HPV 16/18 PROPHYLACTIC CERVICAL CANCER
VACCINE: DEVELOPMENT UPDATE
HansBock
Rationalefordevelopment
HPVtypes16and18aremostfrequentlyassociatedwithcer-
vical cancer, occurring in >70% cases globally [72].
Insomelocations(thePhilippines,CostaRica,Bangkok),
the odds ratio associating HPV and cervical cancer is >10
times that of cigarette smoking and lung cancer [73].
The objective for vaccine development was to prevent
persistent infection with HPV 16/18, and thus avoid abnor-
mal cytological and neoplastic changes in the cervix.
GlaxoSmithKlinebiologicalHPVvaccine
GlaxoSmithKline has produced an HPV vaccine based on
a recombinant L1 protein, which self-assembles into VLPs.
Theseresembleintactvirusesbutarenotinfectious.Thevac-
cine, currently in clinical trials, is the result of an early-stage
collaboration between MedImmune and GSK.
Originally,thevaccinewasproducedusinganaluminium
adjuvant, but in Phase II trials a new adjuvant (AS04) gener-
ated faster, stronger, and longer-lasting antibody responses
against both HPV types. Seroconversion remained at 100%
for24months.Thediﬀerencebetweentheearlieraluminium
adjuvant and AS04 was statistically signiﬁcant.
Earlystudies
All formulations and dosage levels tested in early trials were
well-tolerated, although local injection site reactions were
common. Vaccination generated high levels of HPV 16/18-
neutralising antibodies and CMI responses, particularly the
formulations using the AS04 adjuvant.
The ﬁrst eﬃcacy trial, a double-blind, controlled, ran-
domisedtrial,wasconductedintheUSA,Canada,andBrazil.
More than 1100 women were enrolled; they were aged 15–25
years, claimed no more than six lifetime partners, and were
seronegative for HPV 16/18 and tested negative for HR-HPV
DNA in cervical scrapes.
The vaccine schedule included three doses (0, 1, and 6
months) and participants were monitored for 18 months.
T h eo b j e c t i v e sw e r et o
(i) evaluateeﬃcacyagainstincidentHPV16and/or18in-
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(ii) evaluate eﬃcacy against persistent HPV 16 and/or 18
infection and the development of HPV 16- and/or 18-
associated cytologic and histologic lesions,
(iii) determine vaccine safety, tolerability, and immuno-
genicity.
At 7 months, all vaccinated women showed ELISA responses
that far exceeded those seen in naturally infected women. No
instances of persistent infection were recorded in vaccinated
women [74].
In the vaccine group, there was also statistically signiﬁ-
cant protection against HPV 31, 52, and 45. Types 31 and
52 are phylogenetically related to HPV 16, as HPV 45 is to
HPV 18, yet this was the ﬁrst evidence of cross-protection
between HPV types. The GSK vaccine provides protection
against high-risk HPV types in addition to HPV 16/18.
Cross-protection increases vaccine coverage against cervical
cancer [72].
PhaseIIIefﬁcacystudies
A large Phase III eﬃcacy study will enrol 18000 women, 15–
25 years of age in 14 diﬀerent countries across four global re-
gions. It will be a double-blind, randomised, controlled trial
over 4 years, with Independent Data Monitoring Commit-
tee (IDMC) oversight. Cervical samples for PCR and cytol-
ogy will be taken every 6 months for 4 years. The objective
is to gauge the vaccine’s eﬃcacy in preventing CIN2+, AIS,
and invasive cervical cancer resulting from persistent infec-
tion with HPV 16/18.
The National Cancer Institute will undertake a separate
study that will test ∼12000 women through a single centre
in Costa Rica. Data management will be overseen by an
IDMC.
The programme also includes studies that will extend
vaccination age coverage to 10–55 years. Key data is accu-
mulating to support ﬁling for launch in 2006.
Long-term studies to evaluate the vaccine’s eﬃcacy
against cervical cancer are planned until 2015.
IMMUNOTHERAPY FOR HPV: WHAT IS
NEEDED AND WHY
IanFrazer
Preventingcervicalcancer
The only approach to preventing the consequences of persis-
tent HPV infection currently widely available involves treat-
ment following early detection of CIN. This requires reg-
ular screening using Pap smears, visual inspection, and/or
HPV testing, followed by destructive therapy to kill cancer-
ous cells.
Prophylactic vaccines now in development use VLPs to
prevent infection with speciﬁc HPV types.
It may be possible to use viral nonstructural proteins to
promote the immune response and enhance resolution of
precancerous and early cancer lesions.
ImmunologicaltherapyforHPV
There is considerable research interest in HPV therapeutic
vaccine development. During the next 25 years, 5 million
women who are already infected with HPV will develop cer-
vical cancer. Vaccines have been developed which appear to
work in mice and are immunogenic in humans, but none has
reliably halted or reversed cancer progression.
HPV is a nonlytic virus that does not generate local in-
ﬂammation. The immune response is certainly weaker com-
pared with most other pathogenic viruses.
However, infected cells carry several viral proteins capa-
ble of signalling the presence of HPV. The immune system
recognises a peptide of 8–10 amino acids on the infected cell
surface.
CerVax16
CSL has an experimental therapeutic product, CerVax 16,
which uses E6/E7 proteins identical to those of HPV16 and a
quillaia saponin-based adjuvant capable of promoting both
humoral and cell-mediated immunity [75].
The vaccine has been trialled in a double-blind, dose-
escalation study that was stratiﬁed by HPV16 status. Partici-
pants were 31 women with HSIL smears and, in most cases,
CIN3 lesions.
Vaccination induced an E7 speciﬁc DTH response and
there was a fall in viral load post-vaccination. Anti-E7 anti-
body developed in all vaccinated subjects and most demon-
strated anti-E7-speciﬁc T helper cell responses. However,
during 12 weeks’ followup, there was no change in col-
poscopy and histology. The women were referred for stan-
dard treatment.
Atherapeuticvaccineforgenitalwarts
An HPV6b VLP vaccine has been trialled in Zhejiang
province, China [76]. Women with recurrent genital warts
were treated with three doses of VLPs administered at 4
weekly intervals. There was a DTH response at the injection
site and a rise in HPV6-speciﬁc antibodies. Ten weeks after
ﬁrst immunisation, only 40% of patients still had unresolved
warts. A randomised, placebo-controlled study of VLP vac-
cine as therapy for warts is warranted.
Otherstudies
By 2004, 12 human studies of HPV immunotherapy had
been published. In all but one study, the antigen was derived
from an E6/E7 fusion protein, but the target diseases var-
ied (genital warts [76, 77], anal/cervical dysplasia [78], cervi-
cal cancer, [75, 79–82]V I N[ 83–85]). Although the vaccines
have proven to be well-tolerated and immunogenic, disease
regression has been very inconsistent. Some developmental
products have been named, and are listed here to aid recog-
nition: Xenova (HPV 16); Stressgen (HPV 16); Zycos (HPV
16).Sebastian Faro et al 15
Transplantabletumourmodels
Grafting and transplanting tumours in animals has demon-
strated that eﬀective epithelial immunotherapy requires
(i) eﬀector CD4 and CD8 T-cells,
(ii) IFN-γ,b u tn o tP e r f o r i no rF a s L ,
(iii) an adequate “magnitude of response,”
(i v) localinﬂammation,ev enwhenaneﬀectivecellularim-
mune response is induced.
Conclusions
Therapeutic vaccines to combat HPV infection are at least
a decade away. They appear unlikely to be eﬀective as sole
therapy for HPV-associated tumours. Enhancing innate im-
munity may prove to be as important as generating antigen-
speciﬁc responses.
VACCINATION AGAINST CERVICAL CANCER:
IMPACT ON SCREENING
JackCuzick
Cervicalscreeningissues
Cytology is unfeasible for much of the developing world due
to its cost, inadequate infrastructure and levels of expertise,
and the very high level of inﬂammatory smears (false-posi-
tives). In an example from Recife, Brazil, in 1991, ∼ 63000
women were screened using Pap smears. The incidence of in-
ﬂammatory changes was 71%, compared with 6% of CIN or
cancerous lesions. Only one in ﬁve women recorded “nor-
mal” Pap smears.
Becauseofthelongtimeperiodoverwhichepithelialdys-
plasiasdevelopneoplastictendencies,aprogrammemustop-
eratecontinuouslyandconsistentlyovertimeforgreatestim-
pact on mortality rates.
Prophylacticvaccines
The introduction of commercial vaccines will raise many
strategic questions with regard to cervical cancer prophylaxis
and management.
Target groups
Thereissomedebateoverwhichgroupstotargetforvaccina-
tion,forexample,whetheritshouldbeavailabletoallwomen
or restricted by age or HPV status. Men, who are a reservoir
for HPV virus, may also be considered for vaccination.
Efﬁcacymeasures
While the ultimate goal of HPV vaccination is to reduce can-
cer deaths, it will be a long time before that reduction is
measurable. Success may also be evaluated through levels of
HPVinfection,persistenceofinfection,levelsofCIN,oronly
high-grade CIN.
The durability of protection needs to be evaluated to de-
termine whether boosters will be required to maintain im-
munity following the initial series.
Neither of two vaccines currently in development tar-
gets all HPV types identiﬁed as high-risk for cervical can-
cer. At best, they would only reduce cancers linked to HPVs
16 and 18 (65–75%). To achieve 85% protection, a vaccine
would need to be immunogenic against ﬁve diﬀerent high-
risk HPVs, yet the relative importance of the various HPV
strains in cancer causation diﬀers between regions [35].
The interpretation of diagnostic HPV tests following the
introduction of the vaccine will be more diﬃcult. Follow-
ing vaccination, women would test positive to the HR-HPV
screen used in HC II tests. Over time, there will be a need
for tests capable of distinguishing HPV types 16 and 18 from
other HPV types linked to cervical cancer.
Timelines
Within 1–3 years, the impact of vaccination on CIN2+
should be evident. Proven eﬃcacy against cancer is likely to
require 5 years, and will probably be seen earliest in the de-
veloping world. The eﬀectiveness of vaccination on prevent-
ing persistent infection for the types used remains at 100%
[86, 87].
Vaccination will not reduce the need for regular cervical
screening for at least 10 years, and probably longer, depend-
ing on levels of usage, HPV type distribution within the pop-
ulation, and screening techniques used.
HUMAN PAPILLOMAVIRUS DNA TESTING: WHAT
ARE THE PSYCHOSOCIAL ISSUES?
MarianPitts
A review of the role of HPV testing within a cervical screen-
ing programme identiﬁed “a lack of knowledge about the
psychosocial issues involved in providing cervical screening
in general and HPV testing in particular [69].”
Public support for HPV testing and appropriate infras-
tructure and technology will need to be available before test-
ing can become generalised; perhaps more important will be
general knowledge and understanding.
Of the few studies to examine knowledge of HPV, most
havesampledUSuniversity students.BothRamirezetal[88]
and Baer et al [89] reported very low levels of awareness of
HPV, particularly its link to cervical cancer.
These studies did not compare HPV knowledge with un-
derstanding of cervical cancer and screening. Consequently,
it is diﬃcult to know whether gaps in the knowledge base are
broad or restricted to speciﬁc topics.
Pitts and Clarke conducted a study at a UK university in
2002 to examine knowledge ofHPV in the context ofcervical
cancer, and understanding of the screening process [90].
The sample group of 985 women was 19–64 years of age
(mean = 40 years). Approximately half worked in clerical
or administrative roles; academics, managers, and manual
workers accounted for the remainder.16 Infectious Diseases in Obstetrics and Gynecology
The GP (64.3%) and practice nurse (50.3%) were the
most frequently cited sources of information regarding cer-
vical cancer. However, family/friends (30.5%) and maga-
zines/books (29.3%) were also signiﬁcant.
It was encouraging that when the women were asked
what an abnormal smear might mean, 97% of women men-
tionedabnormal,precancerouscells;39%mentionedcancer;
and 45% mentioned infection. Less than 1% of women said
they did not know.
Two in three women (68%) were aware that a large num-
ber of sexual partners could increase risk, and 60.3% also
mentioned early age of ﬁrst sexual activity. Smoking (45%)
and failure to use condoms (28%) were mentioned by fewer
women.
However, only 30% of sampled women were aware of
HPV, and among the aware minority, knowledge was gen-
erally poor (78% incorrect or no knowledge). Only 30% of
respondents were aware that HPV is a sexually transmitted
disease, and consequently very few participants could cor-
rectly identify risk factors.
In answer to more speciﬁc questions, the majority of re-
spondents admitted they “did not know.” For instance, in re-
sponse to the question “if symptomatic, what are the signs
and symptoms of HPV?,” 90% answered incorrectly or left
the question blank. As for the long-term eﬀects of HPV, only
11% of respondents demonstrated good understanding.
TodeterminewhatwomenwanttoknowaboutHPV,An-
hang et al reported on eight ethnically diverse focus groups
[91].
The women were provided with background informa-
tion before the focus groups met. In discussion, it was evi-
dent that women overestimated the likelihood that HPV ex-
posure would lead to cancer, and struggled to balance this
knowledgewiththeawarenessthatHPVoftenregresseswith-
out treatment. Consequently, they found it diﬃcult to as-
sess personal risk of HPV and cervical cancer, often failing
to understand how a Pap test could be normal in HPV+
women. Younger women focused on sexual transmission of
HPV rather than its potential to cause cancer.
Anhang et al paper suggests that without good commu-
nicationandunderstanding,responsestoadiagnosisofHPV
could include anxiety, anger, regret, and fear [91].
HPVtesting:emotionalandpsychosexualimpacts
Among women who have had a positive HPV test, anxiety
aboutthepotentialforcancerhasbeendemonstratedrepeat-
edly. McCaﬀrey et al found that HPV-positive women were
more anxious and concerned about relationships compared
with HPV-negative women [92].
Although there is no evidence speciﬁcally related to HPV,
the stigma and concern associated with a positive diagnosis
for an STD have been widely reported [93, 94].
Roleofthemediaineducation
In 111 US newspaper stories (1995–2002) on HPV, there was
little information regarding prevention, transmission, and
symptoms. Only a minority of stories mentioned risk factors
for HPV, stated that HPV can be asymptomatic, or included
the frequency of regression without treatment. In fact, only
one in four mentioned that most HPV+ women do not de-
velop cervical cancer.
HPVamonggaymen
A survey in Melbourne, Australia, of 384 well-educated gay
men found little understanding of anal cancer and the role of
HPV[95].Morethanhalfofthoseinterviewedhadnotheard
of an anal Pap smear and/or HPV, suggesting a poor sense of
personal susceptibility to HPV disease.
Among those who were aware, the most common source
of information had been a doctor or other health profes-
sional. The results suggest that health education for gay men
should not be neglected.
Movingforward
Thereisaclearneedforfurtherstudies.Fewevaluationshave
assessed risk perceptions or the likely impact of HPV testing
or vaccination on cervical screening.
As HPV testing becomes more widely available, particu-
larlywiththeadventofvaccines,itwillbeimportanttodeter-
minehowtoeducatethecommunityinaneﬀective,strategic,
and consistent way.
CERVICAL CANCER SCREENING: WOMEN’S
PERCEPTION, PREFERENCES, AND
ACCEPTANCE
ParthaBasu
CervicalscreeninginIndia
Cervical screening is a new concept in India. In order to as-
sess the acceptability of cervical screening, perceptions, and
preferences among women, and reasons for noncompliance
with screening, a review was undertaken wherein women
were oﬀered the opportunity to undergo a free screen.
Screening was undertaken using VIA, VILI, and HCII
tests following counselling, and the service was provided in a
location close to their homes.
Understandingnoncompliance
Five hundred randomly selected women who did not attend
thescreeningprogrammewereinterviewedbyamedicaloﬃ-
cer.Sheusedastructuredquestionnairebaseduponfeedback
from a series of focus group discussions.
The questionnaire included 24 potential reasons for non-
compliance and was undertaken by 469 women, 61% of
whom were illiterate and 75% were housewives. Most came
from poor socioeconomic backgrounds (86%) and the ma-
jority (61%) were <40 years of age.
Reasons for nonattendance varied. Among 232 (49.5%)
women who were unwilling to attend, 46.1% believed that
there was no need for a checkup as they were not sick,
while others expressed fears about the cancer detection test
(36.2%). Some women felt that they might also experience
problems reported by a relative/neighbour following testingSebastian Faro et al 17
(27.6%). Among other responses, the most common was a
fatalistic approach to destiny (18.5%).
Over 40% of nonattendees were willing to accept screen-
ing but could not attend the clinic due to various reasons,
the commonest being work or family commitments. In this
group 26.5% of respondents claimed that their husband/in-
laws did not allow them to be tested. One in 20 women
claimed to have been advised against testing by their doctor.
A small number (5.8%) attended clinic without being
tested; some became impatient with waiting, were scared
by the instruments or refused to be seen by a male doctor
(2.1%).
Post-screeningfeedback
Women (N = 498) from 13 randomly selected villages
who underwent screening were interviewed by a female
social worker. Most reported no pain or only slight dis-
comfort during screening (94.2%). Some experienced post-
screening issues such as burning sensation (5.8%), vaginal
discharge (12%) or bleeding (3.8%). Seven women subse-
quently sought medical attention for post-screening prob-
lems.
The majority of women were satisﬁed with the screening
service (94.6% selected the top three of six rating options)
and 97% said they would recommend the test to others. A
small number (18/498) said their husbands were unhappy
with screening.
The most common reasons for dissatisfaction with the
screening were pain/discomfort during or after screening,
long waiting time, failure to address other health complaints,
and inadequate explanation regarding followup.
Improvingscreening
Noncompliance remains a major barrier to screening in In-
dia, reﬂecting the absence of a preventative health orien-
tation, and the lack of empowerment of women. This re-
view showed that screening is generally well accepted among
women, suggesting it should integrate with primary health-
care.
To maximise the uptake of screening and satisfaction
therewith, the interviewed women made the following sug-
gestions.
(i) Other medical problems should be addressed.
(ii) Medical assistance could be oﬀered to children.
(iii) Medicines should be provided free of charge.
(iv) Female doctors are preferred.
(v) Men should be included in group counselling meet-
ings.
CURRENT PROBLEMS FOR CERVICAL CANCER
SCREENING IN JAPAN
RyoKonno
Startofcervicalcancerscreening
MassscreeningforcervicalcancerwasintroducedinJapanin
the 1960s. In 1982, the government enacted the Health and
1
9
6
0
1
9
6
5
1
9
7
0
1
9
7
5
1
9
8
0
1
9
8
5
1
9
9
0
1
9
9
5
2
0
0
0 0.1
1
50
100
M
o
r
t
a
l
i
t
y
/
(
1
0
0
0
0
0
)
30-34
35-39
40-44
ASR
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85- age
Mortality rate of cervical cancer
by age rank in Japan
Figure 4: Mortality rate of cervical cancer by age rank in Japan.
Medical Service Law for the Aged, which supported annual
screening for all women >30 years of age. Screening uses the
Japanese Society of Obstetricians and Gynaecologist scheme
to classify Pap test cytology with minor modiﬁcation [96].
In Miyagi prefecture [97], the screening rate of the fe-
male population aged >30 years was 0.2% in 1961. There-
after,itgraduallyincreased,andthescreeningratewas30.4%
in 1991. The mortality rate due to cervical cancer fell from
12.1 in 1961 to 4.0 in 1994. In Japan, the age-adjusted mor-
talityrateofuterinecarcinomafellfrom21.3in1960to5.3in
1993. Cervical cancer is the 8th in the rank of cancer deaths
in women. The reduction seemed to be due to the spread of
screening.A1998statementofgovernmentendorsedtheeﬃ-
cacy of screening, stating that furtherreductions in mortality
would occur [96].
Lowcoverageofscreening
However,theJapanesenationalgovernmentstoppedfunding
cancer screening in 1998. At present, the decline in screening
rate is a large problem. The annual screening rate of cervi-
cal cancer nationwide has fallen since 1993, since the oppor-
tunity of appropriate education by government in cervical
cancer decreased [98]. In 1997, some mass media with a lack
of knowledge claimed that mass screening for cervical can-
cer might not be eﬀective. Only 22% of women underwent a
Pap test in 2002 in Japan, whereas among women aged 18–
44 years in the USA, almost 90% had been screened in the
previous 3 years [99].
Increaseincervicalcancermortality
In all ages, the mortality had steadily decreased until 1990,
but changed to an upward trend after 1995. In terms of
age, there is a tendency that the mortality has decreased in
the population aged >50 years but has increased those <50
years since 1990, and the increase is more remarkable in the
younger population (Figure 4)[ 98].18 Infectious Diseases in Obstetrics and Gynecology
Recognising some of the problems associated with cer-
vical cancer screening in Japan, the Anticancer Committee
of the Japan Association of Obstetrics and Gynecologists ap-
pealed for revised legislation. It was proposed that eligibil-
ity for screening be extended in an eﬀo r tt od e t e c tc e r v i -
cal cancer earlier, avoid hysterectomies, and allow women to
conceive. Legislation was revised in 2005 to initiate biennial
screening for women from 20 years of age and to improve
education regarding HPV.
Screening:knowledge,participation,
andmotivation
An internet survey of 2000 randomly selected Japanese
women (20–59 years of age) was undertaken in April 2005.
This was designed to evaluate knowledge of cervical cancer,
motivation for participation in screening, and knowledge of
papillomavirus and tests for HPV.
Over 1000 (51.9%) questionnaires were available for
analysis.
Morethanhalfthewomensurveyedsaidtheyknewabout
cervical cancer and the methods of cervical cancer screening.
A similar number (51.3%) were aware that the incidence of
cervical cancer had increased in Japan in recent years, yet al-
most 60% were unaware that the disease was not terminal
when detected early and treated.
The most frequently mentioned sources of information
were TV/radio, books, and the Internet. Although 49% of re-
spondents said they had been tested for cervical cancer, only
18% were screened annually.
Among women who were not screened, the most com-
mon reasons cited were the troublesome nature, cost or
shame of the procedure, and inadequate time. Very few
women (13%) were aware of HPV or its means of infection.
However, at least three in ﬁve (61%) said they would be
willing to undertake an HPV test.
One hundred and twenty-six respondents made sugges-
tions as to how screening could be improved. Their demands
were mainly for more information and/or funding from the
government to reduce the cost of the tests. Some expressed
the desire for greater protection of privacy (55 mentioned
having a female doctor) and for screening to be easier.
Remarks
There is clearly inadequate education and understanding of
cervical cancer within the community. Furthermore, there
is presently no clear quality direction for the screening
programme—Pap testing is not liquid-based, is not classiﬁed
bytheBethesdasystem,orbackedupwithanHPVDNAtest.
There are no guidelines for SIL management.
Recommendations to improve the system include ex-
tending annual screening to women <30 years of age, with
biennialscreeningforwomen>30yearsfollowingthreecon-
secutive negative tests, or including HPV DNA testing in a
triennial screen [100].
Regardless of the method, more education on cervical
cancer, screening, and HPV is needed.
THE PHILIPPINES: TRAINING NEEDS FOR ANTI-
CERVICAL CANCER MEDICAL EDUCATION AND
COMMUNITY INFORMATION
CeciliaLadines-Llave
ThePhilippines
ThePhilippinesisanarchipelagoof7167islands,withapop-
ulation of more than 87 million people. It is a young na-
tion by age—only 4% of the population are >65 years of age.
Povertyiswidespread,andcommunicationandtransportare
diﬃcult, particularly in rural areas.
Pap smears cost P400 (US$7). The minimum daily wage
is US$3.57 and the average family income is US$221/month.
Preventative health is a luxury.
Twenty million women are aged 25–55, the target popu-
lation for cervical cancer screening. Twenty-three percent of
women have experienced sexual activity by age of 24, includ-
ing 1.2% before age of 13.
CervicalcancerburdeninthePhilippines
CervicalcanceristhePhilippines’fourthmostprevalentcan-
cer, behind lung, breast, and liver tumours.
In a single year, there are over 4500 new cases of cervical
cancer. Most (93.5%) are linked to HPV 16 or 18, and are
not detected until they have become invasive. The incidence
is likely to be underestimated—systematic data gathering is
poor, particularly in rural areas where the majority of the
population (62%) lives. Coverage by the Cancer Registry is
only 25%.
There is no organised and sustained cervical cancer
control programme, and only 12% of the population are
screened. Responsibility for such a programme was recently
movedfromtheDepartmentofHealth(DOH)toLocalGov-
ernment Units. Unfortunately, these units are overloaded
with patients and multitasking reduces their eﬀectiveness.
Educationandlearning
Knowledge about cancer, and particularly cervical cancer, is
poor, due to the lack of readily available responsible public
information and trained medical personnel.
Among the 3600 general practitioner graduates from 39
medical schools each year, 68% leave for overseas, as do 50%
of nursing graduates. Those who do not migrate practice
in urban areas, leaving rural areas under the care of inade-
quately trained health workers. Education regarding cervical
screening must extend beyond doctors to include cytotech-
nologists, gynaecological and oncology nurses, and mid-
wives. In many areas, screening currently relies on barangay
(public) health workers.
Plansforthefuture
A range of options are under consideration to improve pop-
ulation screening for cervical cancer. Before systems can be
expanded dramatically and a public information campaign
is initiated, diagnostic and therapeutic facilities must be able
to cope with increased demand.Sebastian Faro et al 19
The Cervical Cancer Research Project has been planned
as a cooperative venture between local, national, and inter-
national organisations. In 2002, a pilot programme began in
Cebu province, which is now being used as a training centre
for implementation in other provinces. The DOH mandated
the implementation of an improved national screening pro-
gramme in 2005.
A training manual has been developed and guidelines
prepared for setting up clinics. The plan includes a directory
of key contacts and a registry of the target population.
When diagnostic and therapeutic centres are in place
and sustainable, there will be a media campaign to educate
women, with ongoing health education to maintain their in-
terest. Advocacy meetings among medical, diagnostic, more
general interest groups and support groups, are planned. So-
lutions have been identiﬁed for resource and programme
sustainability problems.
SCREENING EXPERIENCES: VISUAL INSPECTION
WITH ACETIC ACID (VIA)
R.Sankaranarayanan
Introduction
Simple and less expensive methods of cervical screening
based on visual examination of the uterine cervix are cur-
rently being investigated as alternatives in low-resource set-
tings. VIA has been widely evaluated for accuracy in de-
tecting CIN 2/3 lesions in research settings in low-resource
countries. Suspicious CIN lesions are characterised by well-
deﬁned acetowhite areas in the transformation zone sur-
roundingthecervicalos,incloseproximitywiththesquamo-
columnar junction, or by acetowhite lesions occupying the
entire cervix. The immediate availability of test results fol-
lowing VIA facilitates the diagnosis and treatment of lesions
in the same session, which has important logistical advan-
tages and ensures a high participation.
AccuracyofVIA
As e r i e so fr e p o r t so nt h eu s eo fV I Ai nS o u t hA f r i c a[ 101–
103], Zimbabwe [104], Iran [105], Egypt [106], Uganda
[107], Cameroun [108], Peru [109], China [110], and India
[111–113] suggests that its sensitivity to detect CIN 2/3 le-
sions ranged from 67–94% and the speciﬁcity from 44–96%.
Pooled data from several studies indicate that the average
sensitivity and speciﬁcity of VIA to detect high-grade cervi-
cal lesions is around 70% and 80%, respectively. VIA had a
similar or higher sensitivity than that of cervical cytology in
many studies in developing countries where both the tests
were concurrently used, although it had a lower speciﬁcity
than Pap smear. Three studies that compared VIA with and
without magniﬁcation provided variable results for speci-
ﬁcityandsensitivity,butnotablyresultswerefairlyconsistent
within each study, indicating that magniﬁcation did not im-
prove the test performance over and above that of naked eye
visualisation [101, 113, 114].
Findingsinrandomisedtrials
The eﬃcacy of a once in a life-time VIA screening in reduc-
ing incidence of and mortality from cervical cancer is be-
ing assessed in two cluster RTCs in India. In one, women
aged 30–59 years in Dindigul district, South India, were ran-
domised to VIA screening by nurses (n = 48225) and to a
control group (n = 30167), which received health educa-
tionandexistingcare[50,115].Ofthe30577eligiblewomen
screened, 2939 (9.6%) VIA-positive women were investi-
gated with colposcopy by nurses and 2777 (9.1%) women
had biopsy. The detection rates of lesions per 1000 screened
women in this study were 58.2f o rC I N1 ,7 .3 for CIN 2-3,
and 2.3 for invasive cancer. Followup of the study groups is
in progress to establish cervical cancer incidence and mortal-
ity.
The second trial, involving 130000 women in Os-
manabad district, Western India, investigated the cost-
eﬀectiveness of a single round of VIA, cytology, and HPV
testing in reducing cervical cancer incidence and mortality
as compared to a control group with usual care (no screen-
ing) [116]. Of the eligible women, 72–74% were screened.
Test positivity rates were 14.0% for VIA, 7.0% for cytol-
ogy, and 10.3% for HPV. The detection rate of high-grade
lesions was similar in all intervention arms (0.7% for VIA,
1.0% for cytology and 0.9% for HPV testing), with 53–67%
of invasive cancers diagnosed in the screened groups during
stage I as compared to 19% in the control group. The total
costs per eligible woman for screening and diagnosis were
US$4.5, US$7.3, and US$12.7 with VIA, cytology, and HPV,
respectively [117]. Between 10% and 24% of these costs were
programmatic, including implementation and management.
The cost per CIN 2/3 detected using VIA compared with no
screening was $775 (95% CI 678–893); the incremental cost
of cytology compared to VIA was US$1135 (95% CI 794–
1958) per CIN2/3 detected [117]. The ultimate eﬀectiveness
of the three approaches will become clear with followup for
cancer incidence and mortality.
Conclusions
Studies indicate that women are willing to participate in and
accept VIA screening, and detection rates of early lesions us-
ing visual testing attest to its validity and usefulness. Good
training is needed to achieve fairly accurate and moderately
reproducibleresultswithvisualtestsindeveloping countries.
Awiderangeofhealthcareprovidersincluding trainedmed-
icalandnonmedicalpersonnelcanprovideVIAafterroughly
5–10 days of competency-based training.
Quality assurance of visual screening in ﬁeld conditions
poses a major challenge. Close monitoring of test positivity
and disease detection rates as well as periodic retraining are
essential to maintain good standards of visual testing. While
a resultant reduction in the incidence and mortality associ-
ated with cervical cancer following VIA screening has not yet
been proven, this is currently being addressed in randomised
screening trials.20 Infectious Diseases in Obstetrics and Gynecology
CERVICAL CANCER SCREENING USING
A COMBINATION OF PAP AND DNA TESTS
MasakiInoue
ThescreeningprogrammeinJapan
A nationwide cancer prevention programme using annual
Pap smears has dramatically reduced cervical cancer inci-
dence and resultant mortality in Japan. However, the Pap test
is not always accurate, and false-negative results can have se-
rious implications. This has led to a reevaluation of the can-
cer screening programme in Japan.
PapwithHCII
A recent study evaluated a combination of Pap smear and
HPV DNA testing for routine cervical cancer screening. The
focus was on Ishikawa prefecture, in the northwest of Japan’s
main island. Kanazawa is the capital of this prefecture, which
has a population of 1.2 million.
More than 8000 women were recruited into the study be-
tween October 2003 and April 2004. Two cytology samples
were taken from the ectocervix using a cytobrush, one for
Pap smear and the other for HPV DNA test. HC II for high-
risktypesofpapillomaviruseswasused,andpositivesamples
were classiﬁed further using the DNA-chip method.
Cytological diagnosis was according to the classiﬁcation
system established by the Japanese Society for Obstetrics and
Gynecology (JSOG). This diﬀers from the Bethesda system
in classiﬁcation terminology, but classiﬁcations IIIa, IIIb, IV,
and V would equate to the ASCUS, LSIL, HSIL, and inva-
sive cancer categories. Colposcopy and biopsy were recom-
mended in all cases catalogued above JSOG II.
H P Vw a sd e t e c t e di n7 %o fw o m e nw i t hn o r m a lc y t o l -
ogy. Overall incidence of HPV infection was 11%. It was
more common for younger women to test positive for HPV
than older women, with 45% of women aged 15–19 years
testing positive. More than 1500 women in their 20s were
tested—24%werepositiveforhigh-riskHPV.Inwomen>40
years of age, levels of infection fell to 4–7%.
There was a higher incidence of Class IIIa cytology
among HPV+ women (74%) than among HPV− women
(41%). Among 26 women whose cytology was normal, but
who had CIN lesions on histology, 23 (88%) tested HPV+.
Among 57 women with abnormal cytology, 86% had CIN le-
sions and 92% were HPV+. This demonstrated the potential
for HPV testing to detect women graded normal with rou-
tine cytological screening, despite serious lesions (CIN3 or
invasive cancer).
TypingHPVinIshikawaprecinct
Those samples that were positive with hybrid capture as-
say were further examined using Biomed-Lab DNA-Chip.
The most frequently detected type of HPV in these Japanese
women was HPV 52, followed by HPV 16.
Almost half the samples were infected with more than
a single HPV type. Multiple infection was more common
among younger women, particularly those in their late teens.
It was more common to ﬁnd multiple infections in
women with CIN lesions than in women with invasive can-
cer.
In 2004, as a result of these ﬁndings, Japan introduced a
new approach to screening for cervical cancer. Samples with
questionable cytology (ASCUS using the Bethesda classiﬁca-
tion system) are routinely examined for HPV DNA. HPV+
women are then recalled for colposcopy.
As in this sample from Kanazawa city, it is clear that the
useofHPVtestinghasimprovedthepositivepredictivevalue
of cervical cancer screening. Among 400 samples that re-
vealedquestionablecytology,50caseswereHPV+ontesting,
so an additional 42 women were referred to colposcopy. This
detected an additional four cases of CIN2 lesions and two
of CIN3 lesions. These six women were treated surgically—
earlier than if the HPV test had not been used.
Changingscreeningpolicies
In conclusion, the combination of Pap cytology and HPV
tests has improved cancer screening eﬃcacy.
The HPV DNA test incurs additional costs. However, for
women who are negative on cytology and HPV, the inter-
screening interval could be extended, thereby recouping the
cost.
THAILAND: CERVICAL CANCER
SCREENING AND EPIDEMIOLOGY
SomkeartSrisupundit
CancerinThailand
Data from 1996 showed that cervical cancer was the most
common cancer in Thailand women, with an ASR of 19.5,
higher than that for breast cancer (ASR ∼ 17.2) [118].
Within Thailand, incidence varies between regions, with
Chiang Mai (ASR 25.6) and Lampang (23.6) having higher
than national levels. The age prevalence is fairly consistent
between regions, peaking at 45–55 years of age.
Unlike more economically developed countries, where
most cervical carcinomas are detected early, only one in ﬁve
Thai cancers will be detected in Stage 1 [119].
In 2005, the cervical cancer incidence was 19.5/100000
women. This equates to 30000 cases of invasive cancer over
a 5-year period. Five women die from cervical cancer every
day in Thailand, and 10 new cases are detected daily.
ScreeningforThailand
Thailand has limited resources for screening. In 2004, a
cytology-based programme was established, which recom-
mended screening every 5 years and aimed to achieve 50%
coverage. The screens were most commonly undertaken at
family planning clinics.
By 2005, the programme was demonstrating coverage
rates of only 10–15%. The lack of cytoscreeners and pathol-
ogists led to long delays in receiving test results, and no ﬁrm
policy had been established to assist healthcare professionals
to deal with abnormal results.Sebastian Faro et al 21
Trainingandtreatment
An intensive and thorough training programme has now be-
gun to build competency in VIA and cryotherapy.
Clinics are encouraged to rely on VIA if Pap smears are
not performed eﬃciently. Ten of the 75 Thai provinces have
adopted this approach. Women 30–45 years of age are en-
couraged to be screened every 5 years. The objective is to
achieve 80% coverage over 5 years.
In Roi Et Province, a concerted eﬀort has been made to
deliver the screening service to women. Mobile units visit ru-
ral health centres. With these intensive mobile units, district
teamsareabletotestthreetimesasmanywomeninaweekas
services at district hospitals. This success has demonstrated
the eﬀectiveness of taking the service to the women, rather
than relying on women to attend screening at a distant loca-
tion.
Health centres staﬀed by 3–5 persons are at the core
of Thailand’s primary care system. They generally provide
approximately 5000 residents from 8–12 villages with ba-
sic medical care and health prevention and promotion pro-
grammes.
Involvement of the health centre staﬀ in cervical can-
cer prevention activities is essential. They identify the target
population by visiting all community households and build
a registry of names of women in the 30–45-year target age
group, to track their attendance at clinics.
The community health centre takes responsibility for or-
ganising, promoting, and coordinating designated cervical
screening days. Staﬀ will inform the local population about
the VIA test using loudspeakers, letters, and presentations.
Healthvolunteersineachvillagealsocontactwomendirectly.
This programme has proved being more reliable and ef-
ﬁcient than any other, and is being expanded to additional
districts and provinces.
KOREA: CERVICAL CANCER SCREENING AND
EPIDEMIOLOGY
HaiRimShin
CervicalcancerinSouthKorea
Since 1980, Korea has had a national tracking system for ma-
jor cancers, which includes site-speciﬁc and regional track-
ing. The database for national cancer incidence is estimated
to be 95% complete.
CervicalcanceristhefourthmostcommoncancerinKo-
rean women. With an AAR of 15.5 in 2001, it is less common
than cancers of the stomach, breast, and colon/rectum.
Between 1993 and 2001, the curves for age-speciﬁc in-
cidence of uterine cancer fell, with this trend most marked
among women 50–70 years of age (Figure 5).
Almost 40% of malignant cervical cases are being de-
tected in situ, before they become invasive. For women di-
agnosed with cervical cancer during the period 1995–2001,
6.6% died within 12 months. Almost 80% survived for at
least 5 years.
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Figure 5: Age-speciﬁc incidence and mortality for cervical cancer
in Korea.
There are local variations in the incidence and mortality
of cervical cancer. Morphologically, the majority of tumours
(∼ 80%) are of squamous cell origin; however, during the 10
years from 1993, there was a growing proportion of adeno-
carcinomas (6.9% in 1993; 10.4% in 2001). The 5-year sur-
vival rate for adenocarcinomas (74.3%) is less than that for
SCC (81.4%).
Epidemiologyandriskfactors
Key factors associated with a lower risk of cervical cancer in
Korean women are [120]
(i) no family history,
(ii) no/few children,
(iii) marriage,
(iv) late ﬁrst sex,
(v) circumcision.
In a review of HPV types in Busan for the IARC HPV Inter-
national Prevalence Survey, the seropositivity of antibodies
to HR-HPV (types 16, 18, 31, 33, and 58) was 19.8% among
sexually active women 20–74 years of age. The most com-
mon types were HPV 70, HPV 33, and HPV 16 [121]. All
seven women with HSIL lesions on cytology tested positive
for HR-HPV.
BusanHPVprevalencestudyinyoungwomen
This trial was undertaken by the Korea National Cancer Cen-
ter with the Unit of Field and Intervention Studies in the In-
ternational Agency for Research on Cancer, in 2002, to de-
termine at what age women become sexually active, exposed
to HPV-DNA, and then seropositive for HPV 16 and HPV
18. It also provided an opportunity to assess willingness to
participate in future HPV vaccine trials.
Students 16–26 years of age attended a health education
class and were asked to complete a survey. They provided a
blood sample and either a vaginal (self-collected) or penile
(physician-collected) swab.
Among 672 females, 15.2% tested positive to HPV, 9.4%
ofwhomtestedpositivetoahigh-risktype.Amongthislatter
group, there was a high frequency of infection with multiple
strains. Among males 8.7% tested positive for HPV [122].22 Infectious Diseases in Obstetrics and Gynecology
Theriskforinfectionclearlyrosewiththenumberoflifetime
sexual partners.
Among this group of 1100 university students, 64% of
men and 58% of women said they would be willing to par-
ticipate in a trial for HPV vaccines.
CervicalcancerscreeninginKorea
Since 1988, medical insurance beneﬁciaries have received a
Pap smear for cervical cancer check as part of their general
healthcheckup.In1999,theNationalScreeningProgrambe-
gan covering Medicaid patients’ screens for stomach, breast,
and cervical cancers. Since this time, coverage has been ex-
panded and about 50% of insured patients are currently in-
cluded.
The current recommendation is that all women >30
years of age should have a Pap smear every 2 years. Partic-
ipation in cervical screening in 2002 was 15.6% and 10.8% in
2003. Incorporation of HPV testing into the screening pro-
cess may improve sensitivity and allow the screening interval
for many women to be extended.
PREVALENCE AND IMPACT OF CERVICAL HPV
INFECTIONS IN TAIWAN
Tang-YuanChu
Taiwan’snationalcervicalscreeningprogramme
In 1988–1992, the AAR of cervical cancer in Taiwan (22.2/
100000) was higher compared with other Asian nations with
Chinese populations, such as Singapore (16.3/100000) and
Hong Kong (15.3/100000).
In 1995, Taiwan instituted the National Cervical Screen-
ing Program for women aged >30 years.
As part of the programme, extensive and ongoing train-
ing has been introduced for cytotechnicians, nurses who
collect samples, and gynaecologists undertaking colposcopy.
To participate in the programme, laboratories and their staﬀ
must be accredited and are reviewed regularly.
Every year since 2000, more than 50% of eligible women
had participated in cervical screening within the previous 3
years. From 9.2% of eligible Taiwanese women screened in
1995, screening levels rose annually until 2001, when 30.1%
of women undertook a screening test; 27.1% of Taiwanese
women were screened in 2003.
When the programme began, cervical cancer levels ap-
pearedtorise from30–35/100000in1995toover50in2000.
This probably reﬂected more frequent diagnosis due to in-
creased screening levels, rather than greater incidence. Fur-
thermore, the AAIR peaked in 1999 and declined in the next
2 years. During the same time period, the proportion of can-
cers that were detected in situ relative to invasive cancers rose
dramatically, reﬂecting earlier diagnosis of the condition.
HPVandcervicalcancerinTaiwan
In 1992, a nationwide survey of more than 13000 women
was undertaken across seven counties and reported by Liaw
et al [123]. This demonstrated the very high incidence of
HPV infection among woman showing cervical abnormali-
ties. Among women without lesions, the incidence of HPV
infection was 9%; among 40 women with CIN1 changes,
HPVincidencewas54%;andamongthosewithCIN2,CIN3,
and invasive cancer (n = 48), the incidence of HPV infection
was 92%. HPV strains 52 and 58 were the most commonly
detected.
Hsu et al reported the results of a population screen
for HPV virus using MY09/11 PCR and sequencing [124].
Among women >55 years of age, the incidence of HPV in-
fection was 19.4%. Age-speciﬁc data from 1999 demonstrate
thehighestlevelsofconﬁrmedcervicalcanceramongwomen
aged 70–74 years, an age where incidence peaked at over
180/100000 women.
The link between infection with HPV and the devel-
opment of cervical cancer is also reﬂected in other results.
Patients who showed SIL on Pap test were eligible for the
study; 1284 women were recruited. Infection with HPV was
conﬁrmed using HCII and PCR-Strip testing. Among those
with low-grade lesions, the incidence of HPV infection was
75%.Thosewithhigh-gradelesionshadanHPVincidenceof
83.6%. All (100%) 16 women with invasive carcinoma tested
positive for HPV.
Further research has evaluated the relative risk of cervical
cancer for diﬀerent strains of HPV. More than half of women
(51%) with cervical SCC tested positive for HPV 16, while
HPVs 18, 58, and 33 were also frequently detected. In cer-
vical adenocarcinoma or adenosquamous carcinomas, HPV
18 was detected in 58.8% and HPV 16 in 35.3% of aﬀected
women. Among 263 cases of cervical cancer in Taiwan, the
majority were linked to ﬁve strains of HPV: 16 (50.7%); 18
(11.9%); 58 (10.1%); 33 (8.4%) and 52 (3.1%).
ASCUS and AGUS abnormalities detected cytologically,
and frequently associated with venereal warts, were also eval-
uated for HPV status (n = 436). Strains of HPV most fre-
quently associated with ASCUS and AGUS cytology were 52
(18%), 16 (15%), and 58 (15%).
Among the Taiwanese population, HPV types identiﬁed
as high risk for cervical cancer are most prevalent, occurring
at more than twice the frequency of all other types of HPV.
In a survey of 4190 people who tested positive for HPV, the
most common types were 52 (22.3%), 16 (11.7%), and 58
(11.2%). Low-risk types were detected in 18.4% of cases.
Compared with other countries, Taiwan has a dispro-
portionately high incidence of HPVs 52 and 58. This dra-
matically contrasts with Europe, where HPV 16 is the
predominant strain. Phylogenetic trees show that diﬀerences
in the origins of HPVs 58 and 52 can be traced in Asian na-
tions such as Thailand, Hong Kong, and Taiwan.
OngoingdevelopmentofTaiwan’sscreeningprogramme
Pilot studies are now underway to investigate the most cost-
eﬀective way to include routine HPV testing in Taiwan’s cer-
vical screening programme. A self-screening test using men-
struation pads is among the options being investigated.
Duetotheextensiverecordingundertakenforthescreen-
ing programme, Taiwan has data to conduct simulationSebastian Faro et al 23
modelling, which can aid planning decisions. The country
has also been involved in trials for HPV vaccines currently in
development. In the short-term, decisions will be made re-
garding frequency of testing (possibly extended to 5 years)
and the timing of HPV testing relative to smears and cytol-
ogy.
Taiwan has already experienced success with a vaccina-
tion to prevent cancer. Following the launch of mass vacci-
nation against hepatitis B, incidence of hepatocellular carci-
noma dropped signiﬁcantly.
As the majority of cervical cancers can be linked to infec-
tion with a few high-risk strains of HPV, vaccination oﬀers
signiﬁcant potential to reduce the incidence of cervical can-
cer in Taiwan.
CLINICAL ALGORITHMS FOR CIN1
LaurieElit
Evidence-basedapproachtoLSILcytologysmears
Emerging evidence has changed the way low-grade cytologi-
cal changes are viewed, but it has not clariﬁed patient man-
agement. Members of the Ontario Cervical Screening Pro-
gram reviewed the available evidence in order to optimise
national guidelines.
The interdisciplinary guideline committee deﬁned a se-
ries of questions regarding the cervical screening process,
withtheaimofdeﬁningtheoptimalmanagementforwomen
with abnormal cytology (up to, but not including, col-
poscopy).
The Appraisal of Guidelines, Research, and Education
(AGREE) process was chosen as the framework for review-
ing the guidelines. AGREE consists of 23 Likert-scale items
organised into six domains, and oﬀers conﬁdence that po-
tential biases in guideline development have been addressed.
Reviewofexistingguidelines
The guideline search and retrieval included some on-
line databases, known guideline developer websites (e.g.,
http://www.guideline.gov and http://www.g-i-n.net), sys-
tematic review websites (e.g., http://www.cochrane.org and
http://www.who.int), and references cited on other materi-
als.
Materials speciﬁc for LSIL included published guidelines
from the American Society for Colposcopy and Cervical
Pathology (ASCCP), 2001 [125], and National Health and
Medical Research Council (NHMRC), 2004 [126]; one RCT;
one meta-analysis; four retrospective studies; and one con-
ference report.
Each source was subsequently evaluated by the panel ac-
cording to AGREE classiﬁcations covering quality, currency,
and content.
The two existing guidelines were subjected to detailed re-
view,whichconsideredtheirscope,stakeholders,rigour,clar-
ity, applicability, and editorial independence.
Every recommendation within the guidelines was re-
viewed according to the level of evidence on which it had
been based. Two diﬀerent ranking systems were used in this
process (Table 6).
LSILcytology
Low-grade lesions present a dilemma when detected during
screening. Half of the women with LSIL cytology will be nor-
mal if checked subsequently after 4–6 months, yet the re-
mainder will progress to HSIL or invasive cancer within 2
years [127].
Three management approaches could be taken for these
patients:
(i) no action, but repeat cytology in 4–6 months,
(ii) immediate colposcopy,
(iii) HPV testing.
TheASCUS/LSILTriageStudy(ALTS)Groupevaluated5000
women to determine how best to manage these early, incon-
clusive lesions. They found that HPV testing was likely to be
positive and would not clarify management.
The ASCCP Guidelines, based on Level CIII evidence,
permitmultiple pathsfollowingLSILcytology,withdiﬀerent
recommendations for teens and postmenopausal women.
Moscicki suggested further revisions to approaches for
adolescents. He believed that LSIL reﬂected an HPV infec-
tion, and commented that “most guidelines in the USA were
overaggressive in their management of abnormal cytology
in adolescents and young women (resulting in) costly over-
treatment” [128]. The median time for HPV clearance is 8–
14 months. A repeat Pap smear 12 months after the LSIL
ﬁnding would allow for 20–25% of cases to regress.
The NHMRC based their 2004 recommendations on
Level CII evidence. If a woman is >30 years of age and has
not experienced negative cytology in the previous 2-3 years,
she should have immediate colposcopy or repeat cytology af-
ter6months.Ifthewomanisonbiennialsurveillanceor<30
years of age with no cervicalcytology history, repeat cytology
screening in 12 months. A woman should be referred for col-
poscopy following two abnormal tests; if the second test is
normal, it should be repeated after 12 months.
AdaptingtheevidenceforCanada[129]
The guideline panel then needed to decide which guideline/s
would best meet Canada’s needs and goals.
ThePrograminEvidence-BasedMedicinerecommended
that women with LSIL on Pap smear should be sent for
colposcopy or repeat cytology after 6 months (B-II). All
women whose cytology is abnormal on the second test
should be referred for colposcopy. If the second Pap test is
normal, it should be repeated again after a further 6 months
and the woman referred if the result is ASCUS or abnormal
(C-III).
Seekingfeedback
Surveys were completed by 180 physicians to review the
guideline proposal. Approximately half agreed that patient24 Infectious Diseases in Obstetrics and Gynecology
Table 6: Coding systems used in reviewing recommendations.
Strength of recommendations Quality of evidence
(A) Good evidence for eﬃcacy and substantial clinical beneﬁt
(I) Evidence from at least one randomised controlled trial supports recommendation for use
(B) Moderate evidence for eﬃcacy or only limited clinical beneﬁt
supports recommendation for use
(C) Evidence of eﬃcacy is insuﬃcient to support a recommendation for (II) Evidence from at least one clinical trial without
randomisation, from cohort or case-controlled analytic
studies, or from multiple time series studies or
dramatic results from uncontrolled experiments
or against use, but recommendation may be made on other grounds
(D) Moderate evidence for lack of eﬃcacy or for adverse outcome
supports a recommendation against use
(E) Good evidence for lack of eﬃcacy or for adverse
outcome supports a recommendation against use
(III) Evidence from opinions of respected authorities
based on clinical experience, descriptive studies,
or reports of expert committees
outcomes would be improved by the proposed changes.
However, there was universal agreement that referring all
LSIL cases for colposcopy would be impractical.
Endorsing,launching,andadoptingtheguidelines
After deciding which people and organisations should en-
dorse the document, plans were made to launch the revised
guidelines in September 2005. Following publication, the
document will be reviewed annually.
Managinganabnormal(CIN1)biopsy
Evidence was reviewed to assess diﬀerent management ap-
proachesforwomenwhohavelow-gradeneoplasiaonbiopsy
(CIN1). Available evidence did not suggest whether it would
be better to followup the ﬁnding at a later date or to treat the
lesion immediately.
Treatment decisions were based on histological results.
However, there was huge variability in how operators coded
their ﬁndings. False-positives and uncertainty lead to unnec-
essary investigations, possible over-treatment, anxiety, and
increased cost.
A number of investigative immunochemistry techniques
oﬀer new insights and potentially more objective founda-
tions for clinical management.
Among the most promising is p16(INK)4a, a protein
marker that is only present in cases of cancer, CIN 2/3, and
CIN1 lesions associated with HR-HPV [130, 131].
As part of a randomised trial in the best manage-
ment strategy for biopsy proven CIN1, cone biopsies (n =
194) were reviewed by ﬁve pathologists and coded [130].
Although there was variability between the pathologists,
p16(INK)4a testing reduced the number of false-negative
and false-positive results.
A study was undertaken to determine whether
p16(INK)4a or other adjuvant techniques might enhance the
evaluation of CIN1 (LSIL) lesions [132]. Following the clas-
siﬁcation of cervical biopsies as CIN1, women were tested
for HR-HPV using HCII and separately for p16(INK)4a.
Five pathologists reviewed the blocks.
Histopathologic diagnosis was most confused when rat-
ing a sample as either CIN1 or normal/reactive. The incon-
clusive samples were more frequently positive for HPV than
for p16(INK)4a.
However, 23% of benign cases were also positive for
p16(INK)4a, and half of these were positive for HPV. On-
going monitoring will reveal the role of p16(INK)4a in these
patients’ disease courses.
A substantial number of CIN1 patients were negative
for p16(INK)4a. Whether p16(INK)4a-positivity has signiﬁ-
cance in terms of natural history requires ongoing followup
of these cases.
CLINICAL ALGORITHMS FOR HSIL
MichaelQuinn
ManagementofHSIL
Approaches to treatment for HSIL depend upon the type of
histology (squamous, glandular, mixed), the size and accessi-
bility of the lesion, the patient’s stage of life and the surgical
options available.
SquamousHSILmanagement
If the whole lesion is not visualised as it involves the endo-
cervical canal, a loop or cone biopsy should be taken. If it is
in range, the lesion can be removed by loop, cone, or surgical
ablation.
If microinvasion or ESI are suspected, the margins on
the biopsy will be important in guiding management. A cold
knife is less likely to denature cells than a loop, and is there-
fore preferred for reviewing margins.
In the case of noninvasive HSIL, either procedure can be
used.Thereislimitedguidanceonwhatendpointdetermines
a successful outcome. Rate of recurrence of CIN is perhaps
the best measure to guide followup.
A Cochrane review reported on 28 trials using diﬀerent
surgical techniques to manage CIN without identifying any
“obviously superior technique [23].”Sebastian Faro et al 25
The LEEP approach has been linked to a number of ob-
stetric diﬃculties. A systemic review that factored in smok-
ing, concluded that following LEEP, women were more likely
to give birth preterm (OR 1.81; P = .006), but there was
no diﬀerence in likelihood of caesarean delivery, precipitous
labour,inductionorneonatalintensivecareadmission[133].
A retrospective cohort study in Nova Scotia, Canada, by
Samson et al reported similar results—LEEP is associated
with an increased risk of preterm delivery, PROM, and LBW
infants in subsequent pregnancies [134].
ANewZealandstudyconcludedthatLEEPandlasercone
treatments were associated with signiﬁcantly increased risk
of PROM [135]. The risk increased with cone length.
Studies atthe Royal Women’s Hospital, Carlton, Victoria,
Canada, indicate that dysplasia itself is associated with pre-
maturity and that all excisional methods increase this risk.
Microinvasivecarcinoma:adisease
ofscreenedpopulations
The FIGO classiﬁcation system for microinvasive carcinoma
has been used since 1995. FIGO Stage 1A tumours are su-
perﬁcially invasive and can only be diagnosed microscopi-
cally. They are diﬀerentiated by depth of invasion and hori-
zontal extension. No consideration is given to vascular space
involvement or to special invasion patterns.
To date, no RCTs have been published comparing man-
agement approaches with outcomes in microinvasive carci-
noma.
When classifying biopsies, processing is critical. Con-
sideration should be given to how the specimen has been
prepared—radial versus sagittal sections, whole specimen,
special stains, and so forth.
In distinguishing ESI from CIN 3, if the margins on a
specimen are clear, there is no indication for hysterectomy.
Seven reports include results on the use of cone resection
alone for ESI. Among 255 cases of FIGO Stage IA1 tumours,
there were six recurrences; of 18 cases of Stage IA2, there were
three recurrences [136–138].
¨ Ost¨ or and Rome reported on long-term outcomes in a
series of women treated for microinvasive carcinoma when
nodeswerepositive.Twenty-threepatientssubsequentlydied
in spite of treatment—those women generally had deeper le-
sions (3–5mm) [138].
Rome and Brown were able to demonstrate the antici-
pated higher risk of recurrence in patients with <3mm in-
vasion where LVSI was identiﬁed pathologically [139]. Rel-
ative risk of recurrence for their sample of 131 LVS-positive
womenwas7.42(CI = 2.36–22.61).For92womenforwhom
the area of invasion was 3–5mm with LVSI, the relative risk
rose to 22.25 (CI = 5.9–57.96) compared with those who
were LVS-negative.
At the Royal Women’s Hospital (RWH) in Melbourne,
Australia, disease management recommendations for mi-
croinvasive lesions are as follows.
(i) If 1–3mm invasion, treat as for ESI, unless LVS is seen.
Consider hysterectomy in postmenopausal women
and when childbearing is complete.
(ii) When the invasive zone is 3–5mm, a hysterectomy is
preferred; however, where fertility is an issue, a cone
resection including lymph nodes is an option.
(iii) In cases where the margins of the biopsy are posi-
tive, and the invasive depth ≤ 3mm, the cone may
be repeated and retested. If CIN is present at the
ecto/endocervix, follow with colposcopy/cytology and
ECC.
Adenocarcinomainsitu
AIS is a recognisable precursor to invasive cancer. It is fre-
quently multifocal and often associated with squamous le-
sions. The predictive value of cytology is 75%. Since the
1970s, the incidence of AIS (relative and absolute) has in-
creased; HPV 18 and oral contraceptives have been impli-
cated.
Soutter et al reported retrospective outcomes for 53
women in England, whose AIS was treated with cone alone
[140]. Ten percent had early invasive lesions detected on sec-
ond cone or hysterectomy. At 4 years, the cumulative inci-
dence of hysterectomy was 21%, so long-term surveillance is
needed postsurgery.
Microadenocarcinoma
This classiﬁcation includes glandular carcinomas such as en-
docervical, villoglandular, intestinal, endometroid, clear cell,
and adenosquamous.
¨ Ost¨ or and Rome reported outcomes for 436 women with
microinvasive adenocarcinoma deﬁned as invasion ≤ 5mm,
and associated with complete obliteration of normal endo-
cervical crypts, extension beyond normal glandular ﬁelds,
andstromalresponse[141].Ofthesewomen,126underwent
radical hysterectomy, not necessarily with simultaneous re-
moval of adnexa. There were 15 recurrences and six deaths
from the disease.
Another report reviewed retrospective data and recom-
mended that, where invasion was <5mm, the likelihood
of lymph node metastasis and disease recurrence were very
small, and therefore conservative surgery could be consid-
ered with some conﬁdence [142].
With the limited data available, the RWH makes the fol-
lowing recommendations.
(i) Conisation is a good approach when lesions are
<3mm.
(ii) Lymphadenectomy is recommended whenever LVS is
positive.
(iii) Recone if there is any uncertainty.
(iv) For lesions 3–5mm, a simple hysterectomy is recom-
mended.
Summary
Adequate data are available to make recommendations for
squamous lesions with conﬁdence. It is likely that adenocar-
cinomas can be managed similarly, although more data are
needed to provide statistical validation.26 Infectious Diseases in Obstetrics and Gynecology
GENITAL WARTS: TREATMENT MODALITIES
SuzanneGarland
GenitalHPVinfection
Genital warts (condylomata acuminata) is one of the most
common STIs worldwide, usually resulting from infection
with HPV types 6 and 11 [143].
The highest rates of genital HPV infection are in sexually
active women <25 years of age. Highest incidence for both
genders is between 18 and 28 years of age [144].
In developed countries, genital HPV infection has in-
creased steadily since the 1950s [144]. About 1% of all sex-
ually active adults have had or currently have genital warts
[143, 144].
Treatinggenitalwarts
There are many ways to remove warts (cryotherapy, dia-
thermy/laserablation,surgicalincision,orwithtrichloracetic
acid), but recurrences are common (30–60%). Antiprolifer-
a t i v ea g e n t ss u c ha sp o d o p h y l l o t o x i no r5 - F Uw i l lc a u s et h e
warts to regress.
There is no speciﬁc antiviral agent for HPV. However,
the immune modulator imiquimod, which has speciﬁc but
broad antiviral activities, has been an approved therapy
speciﬁcally for genital warts and has been endorsed in US-
CDC [145], Latin American [146], European [147], and
Australian [148] antimicrobial guidelines. The cream is a
patient-applied treatment and used on the aﬀected areas,
three times a week.
Imiquimod:modeofaction
Imiquimod induces interferon-alpha in an early, nonspe-
ciﬁc, innate immune response as well as stimulating CMI
[149, 150]. Its antiviral activity mimics the natural immune
response and limits production of HPV; its antiproliferative
activity slows growth of infected keratinocytes.
Activated dendritic cells engulf HPV from infected cells
and process the viral antigens on their cell surface [151].
They leave the skin via draining lymphatic channels. When
they meet and interact with T-cells that have the speciﬁc re-
ceptor for HPV antigens, the T-cells begin to divide and mi-
grate from the lymph node to the bloodstream [149, 150].
Once activated, these HPV-speciﬁc T-cells express the adhe-
sion molecule antigens LFA-1 and VLA-4 on their surface.
Stimulated by the presence of cytokines and chemokines,
T-cells and monocytes migrate toward the site of infection.
The T-cells invade the wart and kill infected cells, which are
then phagocytosed.
The wart gradually clears and immune memory is estab-
lished. This can reduce recurrences, as newly infected ker-
atinocytes will be rapidly killed.
Usingimiquimod:clinicaltrials
A 1998 study reported the outcomes of an intent-to-treat
RCT of self-administered imiquimod cream in 311 patients
with external anogenital warts [152]. The cream was admin-
istered three times per week until clearance, or for a maxi-
mum of 16 weeks. Followup was for an additional 12 weeks.
Amongpatientsusingplacebocreams,11%ofpatients’warts
resolved spontaneously. Among those using imiquimod, to-
tal clearance was achieved in 72% of women and 33% of
men (P<. 0001). If the endpoint was >50% wart reduc-
tion, overall success was 76% for imiquimod patients com-
pared with 28% for placebo. Erythema at the wart site oc-
curred in two-thirds of patients using imiquimod cream,
while smaller numbers experienced erosion (32%), excori-
ation (24%), oedema (16%), and scabbing (15%). Interest-
ingly, erythema was reported by one in four who received the
placebo cream containing no active ingredient.
Another study sought to determine whether subgroup
demographics inﬂuenced treatment outcome [153]. The
conclusion wasthatimiquimod providesasigniﬁcantbeneﬁt
independent of gender, initial wart area, duration of current
outbreak of warts, previous wart treatment, or tobacco use.
However, clearance rate was inﬂuenced by circumcision—it
was∼33%higherinuncircumcisedmales.Thriceweeklyap-
plication was found to be a slightly more eﬃcacious regime
than daily application, achieving total clearance in 62% of
participants. Furthermore, there were fewer reports of ad-
verse events. Erythema, erosion, ﬂaking, or ulceration were
common.
Patients around the world who had previously been
treated using cryotherapy or podophyllin rated imiquimod
superior with regard to its convenience and lack of pain
[154].
A series of trials also demonstrated the eﬃcacy of im-
iquimod as an adjunct to ablation (post-laser ablation [155],
combined with surgery [156], following surgery to remove
anal canal condyloma [157]). It was generally well tolerated
and reduced recurrence rate.
CERVICAL CANCER: RECOMMENDATIONS OF IARC
AlbertSinger
NewIARChandbookofcervicalcancerscreening
The IARC Handbook of Cancer Prevention, Volume 10, was
launched following a meeting in Lyon, France, in April 2004.
The Working Group of the IARC concluded that screen-
ing for cervical cancer by Pap smear eﬀectively prevents
mortality from the disease. However, in order for a cytol-
ogy screening programme to reduce death optimally, it must
be well organised and have quality control at every step
throughout the process. If these prerequisites are met, an es-
t i m a t e d8 0 %r e d u c t i o ni nm o r t a l i t yc a nb ea c h i e v e d .
HPVDNAtesting
The Group also concluded that suﬃcient evidence supports
the eﬃcacy of the HPV DNA test in reducing mortality from
cervical cancer, which is a rare outcome of HPV infection.
Tests for the presence of viral DNA in blood sample can sig-
nalpotentiallyprecancerouslesions.Theidentiﬁcationofthe
role of HPV in the aetiology of cervical cancer has openedSebastian Faro et al 27
Table 7: Impact of screening interval on incidence of disease.
Screening interval
(years)
Reduction in
incidence† (%)
No. of cervical during
lifetime smears
1 93% 45
3 91% 15
5 84% 9
1 smear at 40 years 20% 1
†Assuming 100% coverage for women 20–64 years of age.
new avenues to preventing the disease by screening and vac-
cination. The major challenge lies in developing a simple, re-
liable and aﬀordable test that can be used around the world.
HPV DNA testing is yet to be widely adopted within
screening programmes. The suitability of HPV as the pri-
mary screening test will be inﬂuenced by public acceptability
and cost. As many infections are transient, HPV screening
below 30 years of age is not recommended. HPV testing can
beusedincombinationwithPapsmearsuntillong-termdata
on its eﬀectiveness become available.
Screeningindevelopingcountries
As much of the cervical cancer disease burden lies in the de-
velopingworld,eﬀectivescreeningmethodsneedtobeappli-
cable in low-resource settings. VIA or VILI is being consid-
ered as a primary screening test by many countries, although
there is still insuﬃcient evidence of its eﬃcacy in reducing
mortality at the epidemiological level. The validity of the di-
agnosis depends on the training and skill of the examining
doctors.
Frequencyofscreening
An organised screening programme should cover women
aged 25–65 years. The IARC advises that annual smears
are unnecessary, even with conventional cytology. Screen-
ing of women <25 years of age oﬀers minimal beneﬁt. For
women 25–49 years of age, three-yearly Pap smears are rec-
ommended, or ﬁve-yearly where resources are limited. Five-
yearly smears from 50–65 years of age are recommended;
screening can cease after 65 years of age, provided there are
no suspicious results in the previous two tests (Table 7).
As women with HIV are at higher risk of persistent
HPV infections, they should be screened frequently from a
younger age.
The need for consistency and rapid turnaround in cytol-
ogyisadiﬃcultchallengefordevelopingcountries.Ascreen-
ing programme based on cytology will be successful only
when trained staﬀ can provide eﬃcient diagnosis, and re-
sources are available to investigate and treat abnormal re-
sults. It is hoped that ongoing research will make low-cost,
low technology screening methods viable options for cervi-
cal cancer prevention in these settings.
Newdevelopmentsinscreening
LBC and semi-automation may improve outcomes of cy-
tology screening, depending on local feasibility. Long-term
evaluation and quality control are needed.
New commercial systems based on mRNA require rigor-
ous evaluation before they can be adopted for widespread
clinical use. Furthermore, education for all health profes-
sionals involved in cervical cancer screening will be needed.
PRACTICAL COLPOSCOPY
AlbertSinger
GenitalHPVinfection
To improve colposcopy practice, it is necessary to consider
the accuracy of colposcopy and biases that can arise. Stud-
ies of diagnostic and screening colposcopy provide insights
regarding the validity of visual signs, their reproducibility,
quality control, and how the process is taught.
Those undertaking colposcopy are usually aware that
they are dealing with women whose smears were abnormal,
a population with a higher probability of disease; this predis-
position to look for disease may lead to bias.
Descriptive terms used to deﬁne abnormal colposcopic
ﬁndings may be divided into those considered to be ma-
jor changes and others. Dense acetowhite epithelium, coarse
mosaic, coarse punctuation, iodine negativity, and atypical
vessels are all believed to be major changes.
Accuracyandreproducibility
A number of studies have evaluated colposcopy’s ability
to diﬀerentiate normal from abnormal lesions. Mitchell et
al reported on a meta-analysis, which concluded that the
weighted sensitivity of colposcopy to diﬀerentiate normality
from all other cervical abnormalities was 96% and speciﬁcity
was 48% [158].
In diﬀerentiating low-grade (normal/LSIL) and high-
grade (HSIL/cancer), colposcopy scored 85% for sensitivity
and 69% for speciﬁcity.
To conﬁrm the eﬃcacy of lesion ablation following
colposcopy without histological conﬁrmation, Belinson et
al team reviewed 1997 women in rural China [57]. Key fac-
tors in determining eﬃcacy included the quality of the light
source; adequacy of the operators; cervical characteristics
such as the presence of inﬂammation; and diagnostic thresh-
olds. In another study involving ∼ 8500 women in the same
Chinese province, Belinson et al found that self-sampling for
HPV DNA detection was less sensitive for CIN >2 than the
directcervicalsampleforHPVDNA,butsimilartoLBC[58].
A number of published studies have compared col-
poscopy with other techniques to evaluate its reliability in
screening; conclusions vary dramatically and are clearly in-
ﬂuenced by study design [159–162].
Colposcopicsignsandsigniﬁcance
Reid and Scalzi developed a scoring system based on sharp-
ness of a lesion’s margins alongside colour, vascularisation,
and iodine staining to rate colposcopic ﬁndings [163]. Car-
riero et al found this ranking system to be 86.6% eﬀective
in correctly rating LSIL lesions [164]. A prospective study by28 Infectious Diseases in Obstetrics and Gynecology
Da Forno et al demonstrated the relative signiﬁcance of ace-
towhite colouration, borders and abnormal vessels in colpo-
scopic deﬁnitions of “normality [165].”
Pretorius et al recognised that the most likely reason for
colposcopists to overlook malignant lesions was their size
[166]. When a lesion/lesions extended across more than one
quadrant they were less likely to be under-rated.
Thresholdsofuncertainty
“Assuming colposcopists use the same deﬁnitions, repro-
ducibility of colposcopic assessment depends in part on col-
poscopists using similar “thresholds of certainty” for catego-
rizationﬁndingsastonormalversusabnormalityandgrade.”
(IARC 2005)
Digital photographic databases can retain data for post-
treatment audit and comparison between units.
Education is key to quality colposcopy. Consistency, and
consequently quality, can only be maintained if practition-
ers are taught via rigorous training programmes to adhere to
guidelines, and are regularly accredited.
THE ROLE OF MALES IN TRANSMISSION OF HPV
INFECTIONS AND CERVICAL CANCER RISK
Xavier Bosch
Malesexualbehaviour
Over the years, both social and medical researchers have
found statistical links between observed behaviours and the
incidence of cervical cancer. As early as the 1850s, diﬀer-
ences in incidence were noted between prostitutes and vir-
gins/nuns. During the following century, risk factors for
cervical cancer was related to women whose husbands
(i) travelled as part of their occupation,
(ii) indulged in extramarital sex or multiple marriages,
(iii) had cancer of the penis,
(iv) had a previous wife who had cervical cancer,
(v) were uncircumcised.
The discovery of HPV as a sexually transmitted carcinogen
provided an explanatory context for these observations.
IARCstudies
Spain (AAIR for cervical cancer in 1990 = 7.1/100000),
Colombia (34.4), Brazil (37.7), Thailand (22.4), and the
Philippines (21.6) were selected for the IARC case-control
studies to evaluate the role of males in cervical cancer. Over-
all, 1921 couples were recruited.
The objective was to determine the relationship between
men’s sexual behaviour and penile HPV, and subsequently,
levels of cervical HPV infection and cervical cancer in their
partners.
There were some key diﬀerences in the sexual life and be-
haviour patterns in the countries chosen. Men from South
America generally had more lifetime sexual partners than
men from Thailand, Spain, and the Philippines.
Table 8: Cervical and penile HPV prevalence in control couples.
% HPV-positive
Men Women
Brazil 29.71 7 .3
Colombia 18.91 5 .3
Thailand 9.21 5 .7
Philippines 4.79 .2
Spain 3.55 .4
In addition, men from Brazil and particularly Colombia
were more likely than those from Spain, Thailand, and the
Philippines to have regular intercourse before they were 18
years of age.
HPVprevalence
Men from Brazil and Colombia were far more likely to be
HPV-positive in the distal urethra than men from Thailand,
the Philippines, and Spain. However, this did not necessar-
ily correlate with HPV positivity in their women partners
(Table 8).
The ASRs of cervical cancer within the diﬀerent popu-
lations correlated closely with both the prevalence of penile
HPV and with cervical HPV infections.
The data clearly demonstrate that in countries with low
prevalence of HPV, such as Spain, the risk of cervical can-
cer in women is inﬂuenced by the partner’s sexual proclivity
[167]. However, in Colombia, where the prevalence of HPV
is higher, this is less visible in epidemiological studies, even
when some of the male’s partners may be prostitutes [168].
The interpretation that can be drawn is as follows.
(i) HIGH-RISK countries: HPV prevalence in young
males is very high and any given sexual contact con-
veys a high risk of exposure. When risk of infection
at any given episode of intercourse is high, increasing
thenumberofsexualpartnersdoesnotgreatlyincrease
this already high risk of infection.
(ii) LOW-RISK countries: HPV prevalence in males is low
and only sexual intercourse with high-risk males or a
high number of partners for women conveys a high
risk of HPV exposure.
CircumcisionandHPV
In this study, it was more common for men to be uncircum-
cised (n = 847) than circumcised (n = 292). Uncircumcised
men in the study were >3 times more likely to be positive
for penile HPV (19.6%) than circumcised men (5.5%) [169].
O v e r a l lt h ew i v e so fc i r c u m c i s e dm e nw e r el e s sl i k e l yt od e -
velop cervical cancer (OR = 0.75). The relative risk for cer-
vical cancer in monogamous women with circumcised hus-
bands varied with the men’s sexual proclivity. A wife whose
husband’ssexualbehaviourwasviewedashighrisk(>6part-
ners and ﬁrst sexual encounter before 16 years of age) was
0.18timesmorelikelytosuﬀercervicalcancer;womenwhose
husbands had low-risk sexual behaviour gained no beneﬁt
from his circumcision.Sebastian Faro et al 29
HPVandpopulationdynamics
In future, public health will need to consider the role of the
male in planning management programmes for cervical can-
cer. It is evident that the risks for both infection and cancer
development are inﬂuenced not only by the types and fre-
quency of HPV within a population, but also by sexual be-
haviour. Women who have their ﬁrst stable sexual relation-
ship at a young age (<2 0y e a r so fa g e )h a v eag r e a t e rr i s ko f
cervical cancer.
Societal factors play a major role in sexual relationships,
and in the case of cervical cancer strongly inﬂuence national
epidemiology of HPV-associated disease.
Condoms,HPV,andcervicaldysplasia
Condom use has been associated not only with lower penile
infection rates and regression of penile lesions, but also with
CIN regression and clearance of cervical HPV [170]. In a 2-
year trial of women with CIN lesions (n = 82) regression
occurred in 53% of those whose partners wore condoms,
comparedwith35%ofthosewhosepartnersdidnot.Among
those with condom-wearing partners, 23% cleared the HPV
infection, compared with only 4% of those whose partners
did not wear condoms.
Themalecontributiontocervicalcancerprevention
Males clearly play a role in HPV prevalence within popula-
tions. Cervical cancer rates in women would be aided by any
of the following:
(i) abstinence/monogamy/low promiscuity,
(ii) late sexual debut (particularly in women),
(iii) avoiding high-risk partners,
(iv) consistent use of condoms,
(v) male circumcision,
(vi) vaccination against HPV.
ANOGENITAL HPV INFECTION AND
DISEASE IN HIV-POSITIVE WOMEN
IsabelleHeard
HIVprevalenceinAsianadults
HIV infection is not uncommon in many Asian countries.
At the end of 2003, Cambodia, Thailand, Myanmar, India,
Nepal, and Papua New Guinea had known prevalence levels
>0.5% [171]. As patients continue to survive longer follow-
ingHIVinfection,duetoadvancesintreatment,healthprac-
titioners must consider the implications of anogenital HPV
infection in HIV-positive women.
HPVprevalenceinHIV-positivewomen
A study of women in four US cities found that 60–70%
of HIV-positive women tested positive for HPV, making
them 2.3 times more likely to be infected than HIV-negative
women. They were also 1.9 times more likely to be infected
with multiple HPV strains, and 1.6 times more likely to have
ah i g h e rH P Vv i r a ll o a d[ 172].
WomenwithHIVwerealsomorelikelytohavepersistent
infections with HPV; immunosuppression appears to play an
important role in modulating the natural history of HPV in-
fections [173].
Palefsky et al looked speciﬁcally at HR-HPV types in
HIV-positive women, ﬁnding a prevalence of 20–34% with
an OR of 5.1 compared with HIV-negative women [174].
Immunosuppression in HIV is monitored through the
CD4 count. A lower T-cell count is closely related to likeli-
hoodofinfectionwithHPV,includinghigh-risktypes,ahigh
viral load, and persistence of the infection [172–174].
Cervicaldisease
A number of studies have demonstrated that the prevalence
of cervical cellular abnormalities is signiﬁcantly higher in
HIV-positive women [175–179].
Most cytological abnormalities are ASCUS and low-
grade SIL, with high-grade lesions diagnosed in less than
10%.
Again, risk of cervical disease is greater when HPV load
is high [180] and when immunosuppression is severe [176,
177]. The signiﬁcance of HIV viral load is less consistent—
Massadetalobservednosigniﬁcanteﬀect[177],yetinDuerr
et al study the OR was 7.5[ 176].
Naturalhistoryofcervicaldisease
Infection with HIV increases the incidence of SIL, almost
certainly because HIV-positive women are more likely than
HIV-negative women to have persistent infections with HR-
HPV. A prospective study showed that one in ﬁve HIV-
positive women with no evidence of cervical disease devel-
oped biopsy-conﬁrmed SILs within 3 years [181].
Four studies [175, 177, 178, 182] have attempted to de-
termine whether cervical disease is less likely to regress in
HIV-positive women than in those who are not infected. The
studiesuseddiﬀerentmeasuresandendpoints,andsocannot
be directly compared; however, studies by Massad and Schu-
man demonstrated signiﬁcant HIV-related diﬀerences in the
likelihood of cervical disease regression.
Three studies [175, 177, 178] have shown signiﬁcant dif-
ferences between HIV-positive women and those without
HIV, in progression of cervical disease from LSIL to more
advanced cervical disease.
ImpactofHAART
By maintaining CD4 levels, HAART may impact on the
natural history of cervical disease in HIV-positive women.
However, results of studies are mixed. Women on HAART
were found to be more likely to experience regression of
HPV-linked disease in three studies [180, 183, 184] while
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following antiretroviral therapy [185]. In monitoring cervi-
caldiseaseprogression,Lilloetalbelieveditwasindependent
of HIV treatment [186], while Minkoﬀ et al saw a decreased
likelihood for disease progression (OR 0.68) in women on
HAART [183].
When HIV-positive women are treated surgically for
CIN, they are more likely to experience recurrence of dis-
ease than HIV-negative women. Cited recurrence rates have
ranged from 39% to 56%, regardless of CIN severity or the
mode of treatment (excision versus ablation). The prime fac-
tor inﬂuencing rates of recurrence is the level of immunod-
eﬁciency. Recurrence is halved in women on HAART. The
conclusion was that although surgery is highly eﬀective for
immunocompetent patients, it only prevents progression to
cancer in HIV-positive women [187]. Disease recurrence
should be anticipated in immunocompromised patients.
Invasivecervicalcarcinoma
Case reports of invasive cervical cancers in patients with
AIDS led the CDC to include cervical cancer as an AIDS-
deﬁning illness in 1993 [188, 189].
The risk of ICC among HIV-positive women means that
more frequent testing is justiﬁed. In a prospective preven-
tative study, six-monthly testing was undertaken in women
with CIN1 lesions. These infrequently progressed in women
with HIV, so observation appears safe, in the absence of
other indications for treatment [190]. In a Swiss study, HIV-
positive women had a higher level of cervical cancer than
HIV-negative women (standardised incidence ratio [SIR] =
8.0); however, unlike some other AIDS-related cancers (Ka-
posi sarcoma, non-Hodgkins lymphoma), HAART did not
haveastatisticallysigniﬁcantimpactonICCincidence[191].
HPV-relatedvulvo-vaginaldisease
Women with HIV are more likely to experience VIN than
HIV-negative women (4.67 versus 1.31/100 person years)
[190]. Incident VIN is more common among women who
have cervical lesions.
HIV-positive women are also at a higher risk for both in-
vasive and in situ vulvar cancers (relative risk = 5.8v e r s u s
3.9)[192].Youngerwomen(<30yearsofage)appeartohave
an even higher risk.
Analdisease
Anal HPV infection is frequent (76%) in HIV-positive
women [193]. Prevalence of AIN is also high (26%), partic-
ularly when immunodeﬁciency is severe (CD4 <200mm3)
and cervical disease is also present [194]. A European study
also reported the high risk of anal cancer among HIV-
positive women (SIR = 18.5) [191].
ScreeningtestsinHIV-positivewomen
Because the Pap test has a 10–25% false-negative rate irre-
spective of HIV status, LBC may provide higher sensitivity
than standard cytology. HPV testing may be undertaken at
the time of the swab, and should certainly be used to review
ASCUS samples.
In HIV-positive women, more frequent screening is rec-
ommended if HPV infection is known, there has been a pre-
v i o u sa b n o r m a ls m e a r ,i fC D 4<200, or following any surgi-
cal treatment for cervical lesions.
ManagingHPV-relatedanogenitallesions
Colposcopy should be used routinely in all HIV-positive
women with a known HIV-positive status, if immunosup-
pressed (CD4 <200) and following an abnormal Pap smear
[195]. The entire lower genital tract should be reviewed and
biopsies taken. Following surgical treatment for cervical le-
sions, four-monthly colposcopy is recommended.
Because colposcopy is a subjective science and prone to
false-negatives and -positives, biopsies should be considered
early on in the evolution of any abnormality.
Anal Pap smears have not been adopted in the USA.
High-resolutionanoscopycanbeconsidered,andanyabnor-
mal areas sampled.
Vulvo-vaginal treatments for HPV-related lesions vary in
eﬃcacy. Even in immunocompetent patients eﬃcacy ranges
are broad (20–80%). The overall response to many treat-
ments is likely to be lower in HIV-positive patients, and re-
currence is 3.3 times more frequent.
In the case of AIN, treatment decisions are based on size
of the lesion, its location, and grade of histology. In manag-
ing these lesions in HIV-positive women, the least aggressive
approach is preferred. Radiation therapy should be avoided
in the absence of invasive cancer.
Treatment of CIN and AIN should not be modiﬁed for
patients on HAART, nor should antiretroviral therapy be in-
stituted or modiﬁed as part of treatment.
SINGLE VISIT APPROACH TO CERVICAL CANCER
PREVENTION: LESSONS FROM THAILAND
KhunyingKobchittLimpaphayom
Goalsandobjectivesofcervicalscreening
The primary goal for Thailand is to reduce cervical cancer
andmortalitybydetectingdiseaseearly,andtreatingitbefore
it progresses to invasive cancer.
Thailandhas∼15millionwomenatriskforcervicalcan-
cer, only 5% of whom have been screened in the previous 5
years via the Pap smear campaign. A major problem is the
shortage of trained cytopathologists to examine Pap smears,
and limited resources to followup women with positive Pap
test results.
Thesingle-visitapproach
In considering an alternative to conventional cytology, social
and logistical in addition to medical challenges need to beSebastian Faro et al 31
met. Key components to be addressed include
(i) outreach and education—to increase demand and en-
hance coverage,
(ii) advocacy and policy—to ensure support for the pro-
gramme,
(iii) training,
(iv) service delivery system—to ensure women have access
to screening and treatment that are acceptable to them
and sustainable over time,
(v) a referral system—for women with advanced disease,
(vi) information management—to monitor progress,
(vii) equipment procurement, repair, and maintenance.
A single-visit approach to cervical cancer prevention, link-
ing screening and treatment, is appropriate for low-resource
settings. This can be implemented at the lowest level of the
health system, can be performed by trained nonphysicians,
requires few materials, and is relatively inexpensive. This ap-
proach also avoids the delay of sending specimens away for
testing.
VIA is now established as a safe, eﬀective, viable alter-
native to cytology-based screening for low resource settings.
Cryotherapy using a CO2-based system can be oﬀered to
any woman with abnormalities at the time of the screening.
There may not be a conﬁrmed pathological diagnosis, but
it is the intervention, rather than the diagnosis, that will pre-
ventcervicalcancer.Thus,althoughVIAmaynotbethemost
accurate test, it is the most eﬃcient way to provide preventa-
tive services to the majority of women at risk.
The major advantage is cost savings. A single visit ap-
proach is likely to be more eﬀective and more cost-eﬀective
than multiple visit strategies. A once-in-lifetime test for all
women could reduce cervical cancer incidence and mortality
by up to 25%, dependent on coverage and age groups tar-
geted. Good outcomes have been achieved in settings with a
high prevalence of HIV [196–198].
TheSAFEdemonstrationproject
In 1999, a trial project based on the single visit approach was
initiated in Roi Et province. The safe, acceptability, feasibility
(SAFE) project was very successful. Three in four targeted
women presented to hospital and mobile clinics in the ﬁrst
12 weeks, exceeding recruitment goals (Figure 6).
Trainedandmotivatednursesscreened5999womenover
6months;13%werepositivewithVIAandoﬀeredtreatment.
Following their experience with SAFE, treated women
were surveyed; <2% felt they were not adequately informed
about the treatment, or were not satisﬁed about their deci-
sion to be treated. Most importantly, 96.6% said they would
recommend the service to friends and family.
After screening or treatment, 4.9% of women presented
again. Only 2.7% of visits concerned a minor complication
such as vaginitis, cervicitis, or cramping, and there were no
major complications.
Eﬀorts are now focused on training more local nurses in
VIA and cryotherapy. By May 2005, ∼ 100000 women 30–
45 years of age had been tested with VIA, and 8–10% were
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Figure 6: Recruitment—Roi Et trial project, 1999.
oﬀered treatment with cryotherapy. Ten Thai provinces have
now adopted the single visit approach to screening.
Keysforsuccess
Four key actions have contributed to the success of the single
visit approach in Thailand.
(1) Recognition of the importance of linking testing to
treatment.
(2) Use of competency-based training methods to pre-
pare service providers, clinical supervisors, and master
trainers.
(3) Use of mobile and static clinics for service delivery, en-
suring easier access for women.
(4) Communication to build national consensus and sup-
port for the programme.
GLOBAL CERVICAL CANCER CONTROL
EdwardTrimble
Globalneedsforcancercontrol
Four key areas will contribute to global cancer levels in com-
ing decades:
(i) oncological infectious agents, that is, HBV, HPV, HIV,
Epstein Barr virus, schistosomes, and Helicobacter py-
lori,
(ii) carcinogens, most notably tobacco,
(iii) lifestyle changes, particularly growing obesity and de-
creased exercise and physical ﬁtness,
(iv) changing age structure in many societies—smaller
families and longer life-spans mean that cancer, gen-
erally a disease of old age, will grow in prevalence.
Theglobalcommitmenttocancercontrol
Cancer control is a continuum where improved outcomes
can be achieved at many diﬀerent levels:
(i) prevention,
(ii) screening/diagnosis,32 Infectious Diseases in Obstetrics and Gynecology
(iii) treatment,
(iv) symptom management and health-related quality of
life leading to prolonged survival,
(v) end-of-life care.
A number of global organisations are working with national
and local groups to develop cancer control programmes that
involve stakeholders at all levels, are appropriate to the pa-
tient population, and are achievable and sustainable.
Organisations that have publicly stated their commit-
menttocancercontrolincludetheWHOIARC,WorldChar-
ter Against Cancer 2000, WHO World Health Assembly, and
the International Union Against Cancer.
GLOW
The Global Initiative on Women’s Cancer (GLOW) has iden-
tiﬁed three areas of focus—gynaecological cancer (especially
cervical), breast cancer, and tobacco control.
GLOW supports a number of initiatives for cervical can-
cer and is developing appropriate guidelines for their adop-
tion:
(i) prevention with prophylactic HPV vaccines,
(ii) screening,
(iii) new diagnostic tests,
(iv) treatments to cure or prolong survival,
(v) Palliative care.
Another key focus for GLOW is education through publi-
cations, websites, meetings, and satellite symposia at major
obstetrics/gynaecology and oncology meetings. GLOW can
also provide technical expertise in planning, implementa-
tion, and evaluation of cervical control programmes.
The short-term agenda for GLOW includes
(i) establishing a database for country-speciﬁc needs as-
sessment,
(ii) integratingcervicalcancercontrolintonationalcancer
plansandhealthprogrammes—includinggovernment
support and early adoption of HPV vaccination,
(iii) improving availability of treatment and care—by
building on existing resources to ensure that cervical
cancer screening is part of health promotion for older
women.
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